<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003902" GROUP_ID="AIRWAYS" ID="747899082510343682" MERGED_FROM="" MODIFIED="2014-06-05 16:34:38 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;CJC signed off on 15 May and Toby has already sent this to Paul&lt;br&gt;---------------------------------------------------------------------------------------------------------------&lt;br&gt;FRAM comments 7 May 2002&lt;/p&gt;&lt;p&gt;All issues highlighted by Chris answered. Revised review given back to CJC on 7/5/2002.&lt;/p&gt;&lt;p&gt;Felix &lt;/p&gt;&lt;p&gt;---------------------------------------------------------------------------------------------------------------&lt;br&gt;Technical Editing by CJC 7/5/2002&lt;/p&gt;&lt;p&gt;Authors and contributions: fine&lt;/p&gt;&lt;p&gt;References: fine&lt;/p&gt;&lt;p&gt;Table of included studies: fine - lots of useful data for the readers. I note that many studies excluded reversible patients and all were cross-over in design.&lt;/p&gt;&lt;p&gt;Metaview Labels: The labels are all fine.   I notice that there are change from baseline and absolute lung function results combined as WMD but as the variability is very similar the weights look reasonable and this has the advantage of being easy to interpret clinically. &lt;br&gt;&amp;gt;&amp;gt;Please switch off the totals in Outcome 18 and 23 as the patients are being double counted.&lt;br&gt;&amp;gt;&amp;gt;Please change default to RR for dichotomous outcomes.&lt;br&gt;&amp;gt;&amp;gt;Please switch off the totals for single study outcomes. &lt;/p&gt;&lt;p&gt;Synopsis:-  Great&lt;/p&gt;&lt;p&gt;Text of the review: - &lt;br&gt;&amp;gt;&amp;gt;Please change the results for adverse events to quote just nausea as the pooled total is invalid. RR 7.67 (1.47 to 39.94) for nausea.&lt;br&gt;&amp;quot;It was intended to analyse separately trials employing a crossover design from trials using a parallel-group design. If first-arm data from crossover trials was reported or if we had been able to obtain this data from the authors than this would have been combined with data from parallel design trials. In the event, all the trials were crossover in design, and summary statistics were used.&amp;quot;&lt;br&gt;&amp;gt;&amp;gt; Please clarify that data from both arms were entered and pooled.&lt;br&gt;&amp;quot;Patient preference for theophylline or placebo [Comparison 01:21]&lt;br&gt;Two studies with a total of 100 subjects (Anderson 1982, Mulloy 1993) reported that subjects preferred theophylline to placebo (OR 3.51; 95%CI = 1.48,8.34). &amp;quot;&lt;br&gt;&amp;gt;&amp;gt;Please change this to RR in the text and Metaview.&lt;br&gt;&amp;quot;The risk of experiencing any of the above-mentioned adverse effects was significantly increased when on treatment with theophylline (RR 3.67; 95%CI = 1.33,10.10).&amp;quot;&lt;br&gt;&amp;quot;SIGNIFICANT FINDINGS WITH ONLY ONE INCLUDED STUDY: &lt;br&gt;Trapped gas volume (WMD -0.79; 95%CI = -1.19,-0.39) &amp;amp; heart rate (WMD 6.70; 95%CI = 0.14,13.26). &amp;quot;&lt;br&gt;&amp;gt;&amp;gt;Please remove both the above from text.&lt;/p&gt;&lt;p&gt;given to Felix on disc today to update.&lt;br&gt;---------------------------------------------------------------------------------------------------------------&lt;br&gt;FRAM comments 17 April 2002&lt;/p&gt;&lt;p&gt;The suggested revision to the section &amp;quot;Implications for research&amp;quot; has been made. As requested I have asked Toby to send the review to CC and PJ.&lt;/p&gt;&lt;p&gt;-----------------------------------------------------------------------------------------------------------------&lt;br&gt;PJP comments 17 April&lt;br&gt;Well done- comments noted and agreed. Have gone thru once more- corrected a couple of typos.&lt;/p&gt;&lt;p&gt;Please check the implications for research outcomes- I have added exacerbations - what do you mean by complications that wouldn't already be covered by adverse effects? Should probably include health care utllisation and cost effectiveness analysis to this list too.&lt;/p&gt;&lt;p&gt;Please send off to Chris and Paul once this is addressed!&lt;br&gt;Well done&lt;/p&gt;&lt;p&gt;Phillippa&lt;/p&gt;&lt;p&gt;-----------------------------------------------------------------------------------------------------------------&lt;br&gt;FRAM comments 15 April 2002&lt;/p&gt;&lt;p&gt;Dear Phillippa,&lt;/p&gt;&lt;p&gt;Thank you for your comments. Please find our reply in CAPS below.&lt;/p&gt;&lt;p&gt;Kind regards&lt;/p&gt;&lt;p&gt;Felix&lt;/p&gt;&lt;p&gt;-----------------------------------------------------------------------------------------------------------------&lt;br&gt;PJP comments 4 April 2002&lt;/p&gt;&lt;p&gt;Fantastic job Felix and Sonia. This is really well done, and a major effort. There are few suggested revisions.&lt;/p&gt;&lt;p&gt;THANK YOU&lt;/p&gt;&lt;p&gt;I have gone through and corrected a few typos and minor syntax / stylistic/tense changes with no effect on meaning.&lt;/p&gt;&lt;p&gt;THANK YOU&lt;/p&gt;&lt;p&gt;Please check my suggestions in background/ abstract/ synopsis/discussion/implications for better readability.&lt;/p&gt;&lt;p&gt;THE ABSTRACT HAS BEEN SHORTEN TO NEAR 250 WORDS AS THAT IS THE LIMIT. THANK YOU FOR YOUR OTHER SUGGESTIONS.  &lt;/p&gt;&lt;p&gt;Also amended statistical analysis to reflect that all trials were cross overs.&lt;/p&gt;&lt;p&gt;OK &lt;/p&gt;&lt;p&gt;Please check/correct/comment on:&lt;/p&gt;&lt;p&gt;I don't have the original protocol - are the primary outcomes the same as in the protocol, and what was your rationale for choosing these three as primary outcomes?  The only primary outcome with a significant result is FEV1- Chris Cates may argue that this should not be a primary outcome at all, although I am sure that when most of these studies were done (and judging by the number of inlcuded studies in this comparison), this would have been a (the) primary outcome, as you suggest. Stronger conclusions can be drawn from primary outcomes, less strong from secondary. So, we are somewhat limited in strength of conclusions that can be drawn as most evidence of effect of theophylline from this overview comes from secondary outcomes. &lt;/p&gt;&lt;p&gt;PRIMARY OUTCOMES ARE SIMILAR TO THE PROTOCOL WITH ONE TYPO. INSTEAD OF FEV1 IT SHOULD READ &amp;quot;LUNG FUNCTION MEASUREMENTS (E.G. FEV1, FVC, ETC)&amp;quot;. CHANGED IN TEXT.  ALSO PLEASE REMEMBER THAT WHEN THE PROTOCOL WAS ORIGINALLY WRITTEN WE DID NOT SEPARATE INTO PRIMARY AND SECONDARY OUTCOMES. RATIONAL FOR CHOOSING THE PRIMARY OUTCOMES WAS THE REQUIREMENT TO CHOOSE PATIENT CENTRED OUTCOMES (I.E. HEALTH STATUS AND EXERCISE CAPACITY) AND DUE TO THE NON-BRONCHODILATOR EFFECTS OF THEOHPYLLINE, WE ALSO ADDED ANOTHER OUTCOME (I.E. FEV1) THAT WE CONSIDERED OF POSSIBLE IMPORTANCE AND LIKELY TO BE REPORTED BY MOST STUDIES. &lt;/p&gt;&lt;p&gt;There is an issue with outcomes as the only lung function one you list is FEV1, yet you have analysed and discussed a host of others- suggest you change the second outcome to FEV1 and other measures of pulmonary function. It is important to include all these as they do provide insight into how theo may work. If the original protocol said only FEV1, you could state that you had originally intended to study only FEV1 however, there were a number of other pulmonary function measures reported in the trials which are inlcuded in this review.&lt;/p&gt;&lt;p&gt;CORRECTED TO READ: &amp;quot;LUNG FUNCTION MEASUREMENTS (E.G. FEV1, FVC, ETC)&amp;quot; AS IN ORIGINAL PROTOCOL.&lt;/p&gt;&lt;p&gt;Please comment on the extent of agreement between the two of you with respect to included trials&lt;/p&gt;&lt;p&gt;ADDED SENTENCE UNDER HEADING: METHODOLOGICAL QUALITY OF INCLUDED STUDIES&lt;/p&gt;&lt;p&gt;Suggest leave out Background para 2 second sentence- uncertainty as to benefit-there is enough justification to do the review without adding this line.&lt;/p&gt;&lt;p&gt;SENTENCE DELETED&lt;/p&gt;&lt;p&gt;Can you put in the updated GOLD guideline on use of  theophylline in stable COPD, and appropriate reference. I have it if you don't.&lt;/p&gt;&lt;p&gt;DONE WITH THE CURRENT WEB ADDRESS AND ADDED THE LATEST CITATION OF THE GUIDELINES&lt;/p&gt;&lt;p&gt;Comparison 01 10 PaO2 - this is O2 tension,not O2 saturation. Can you change the title.&lt;/p&gt;&lt;p&gt;TYPO, CORRECTED&lt;/p&gt;&lt;p&gt;Why are Mahler data so different? changes from baseline? If so, should be using SMD?&lt;/p&gt;&lt;p&gt;ALTHOUGH THE MAHLER DATA IS THE DIFFERENCE BTWEEN THE TWO GROUPS (FROM BASELINE) THEY CAN BE COMBINED WITH OTHER DATA FOR END OF STUDY RESULTS (ASSUMING WITH RANDOMISATION BASELINE DIFFERENCES ARE MINIMAL). THIS IS BECASUE THEY ARE BOTH MEASURED ON THE SAME SCALE (UNITS FOR BOTH ARE MMHG) AND REVMAN SUBTRACTS THE TWO GROUPS PER STUDY TO WORKOUT THE WMD. IF YOU HAVE A LOOK AT THE ALLOCATED WMD'S FOR EACH STUDY, YOU MAY BE ABLE TO UNDERSTAND WHAT I AM TRYING TO SAY. THE END RESULT IS THE SAME WHETHER WE ENTER DIFFERENCES OR END OF STUDY DATA.    &lt;/p&gt;&lt;p&gt;Comparison 01 11 PaCO2- same comments- tension and not saturation- again Mahler data stand out ? changes?&lt;/p&gt;&lt;p&gt;TITLE CHANGED. FOR MAHLER STUDY SEE TEXT EARLIER&lt;/p&gt;&lt;p&gt;&lt;br&gt;Is the Guyatt data on CRQ not available in any of the publications? Has he been contacted?&lt;/p&gt;&lt;p&gt;GUYATT HAS BEEN CONTACTED. THE DATA FOR CRQ IS NOT IN ABSTRACTABLE FORM IN ANY OF THE PAPERS AND THERE ARE MANY POST-HOC TYPE ANALYSIS FOR VARIOUS REASONS IN HIS STUDIES.&lt;/p&gt;&lt;p&gt;In the results section- it is a bit redundant and possibly misleading to say for each result that there were e.g. 2 studies with 156 patients in each study group- these are the same patients acting as their own controls, so there were a total of 156 patients - see  the preference result for suggested wording.&lt;/p&gt;&lt;p&gt;PHRASE &amp;quot;IN EACH GROUP&amp;quot; REMOVED FROM ALL OUTCOMES&lt;/p&gt;&lt;p&gt;Suggest use &amp;quot;subjects&amp;quot; instead of &amp;quot;patients&amp;quot;&lt;/p&gt;&lt;p&gt;I REMEMBER US MOVING AWAY FROM THE USE OF &amp;quot;SUBJECTS&amp;quot; BUT RATHER TO &amp;quot;PATIENTS&amp;quot; OR &amp;quot;PARTICIPANTS&amp;quot;. THIS ISSUE WAS RAISED COUPLE OF YEARS AGO BY THE CONSUMER GROUP (I THINK).&lt;/p&gt;&lt;p&gt;Well done&lt;br&gt;THANK YOU AND ALSO THANK YOU FOR YOUR TIME AND HELP&lt;/p&gt;" NOTES_MODIFIED="2014-06-05 16:33:17 +0100" NOTES_MODIFIED_BY="Emma Welsh" REVIEW_NO="THEO-COP" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-06-05 16:32:28 +0100" MODIFIED_BY="Emma Welsh">
<TITLE>Oral theophylline for chronic obstructive pulmonary disease</TITLE>
<CONTACT>
<PERSON ID="8583" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Toby</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Lasserson</LAST_NAME>
<SUFFIX>MSc</SUFFIX>
<POSITION>Senior Editor</POSITION>
<EMAIL_1>tlasserson@cochrane.org</EMAIL_1>
<EMAIL_2/>
<URL>www.editorial-unit.cochrane.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Editorial Unit</DEPARTMENT>
<ORGANISATION>The Cochrane Collaboration</ORGANISATION>
<ADDRESS_1>11-13 Cavendish Square</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>W1G 0AN</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 207 183 7503</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 207 183 9163</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-06-05 16:31:54 +0100" MODIFIED_BY="Emma Welsh">
<PERSON ID="19428" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Felix</FIRST_NAME>
<MIDDLE_INITIALS>SF</MIDDLE_INITIALS>
<LAST_NAME>Ram</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Respiratory Medicine &amp; Clinical Pharmacology</POSITION>
<EMAIL_1>fsfram@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Health Sciences</DEPARTMENT>
<ORGANISATION>Massey University - Auckland</ORGANISATION>
<ADDRESS_1>24 Portsea Place</ADDRESS_1>
<ADDRESS_2>Chatswood, North Shore</ADDRESS_2>
<CITY>Auckland</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1>+64 9 419 6435</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7702" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jones</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>pjones@sgul.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Medicine</DEPARTMENT>
<ORGANISATION>St George's Hospital Medical School</ORGANISATION>
<ADDRESS_1>Cranmer Terrace</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SW17 0RE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 8725 5371</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 8725 5955</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19412" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jose</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jardim</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>josejardim@pneumo.epm.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Disciplina de Pneumologia</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Botucatu 740 - 3o. andar</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>04023-062</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DF44E1F482E26AA20107972467043D0D" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Aldemar</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Castro</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>aldemararaujocastro@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Public Health</DEPARTMENT>
<ORGANISATION>State University of Heath Science</ORGANISATION>
<ADDRESS_1>113, Jorge de Lima Street Trapiche</ADDRESS_1>
<ADDRESS_2/>
<CITY>Maceió</CITY>
<ZIP>57010382</ZIP>
<REGION>Alagoas</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+5582 3326 2922</PHONE_1>
<PHONE_2/>
<FAX_1>+55 82 3326 2922</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5183" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Álvaro</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Atallah</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Director of Brazilian Cochrane Centre</POSITION>
<EMAIL_1>atallahmbe@uol.com.br</EMAIL_1>
<EMAIL_2>alvaro.atallah@gmail.com</EMAIL_2>
<URL>www.centrocochranedobrasil.org</URL>
<MOBILE_PHONE>+55 11 98173 0404</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Centro de Estudos de Medicina Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION>
<ADDRESS_1>R. Borges Lagoa, 564 cj 63</ADDRESS_1>
<ADDRESS_2>Vila Clementino</ADDRESS_2>
<CITY>São Paulo</CITY>
<ZIP>04038000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5571 4721</PHONE_1>
<PHONE_2>+55 11 5575 2970</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5351" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Yves</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lacasse</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Service of respirology</POSITION>
<EMAIL_1>Yves.Lacasse@med.ulaval.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institut Universitaire de Cardiologie et de Pneumologie de Québec, Hôpital Laval</ORGANISATION>
<ADDRESS_1>2725 Chemin Sainte-Foy</ADDRESS_1>
<ADDRESS_2/>
<CITY>Québec</CITY>
<ZIP>G1V 4G5</ZIP>
<REGION>Quebec</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 418 656 4747</PHONE_1>
<PHONE_2/>
<FAX_1>+1 418 656 4762</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5287" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roger</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Goldstein</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>rgoldstein@westpark.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Respiratory Medicine</DEPARTMENT>
<ORGANISATION>West Park Healthcare Centre, University of Toronto</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2>82 Buttonwood Avenue</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M6M 2J5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 243 3600 ext: 2719</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5143" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sonia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cendon</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cochrane.dmed@epm.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Disciplina de Pneumologia</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Botucatu, 740. 3.0 Andar</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>04023-062</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 556 15966</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-26 16:57:34 +0100" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Minor update: 1/24/03&lt;/p&gt;&lt;p&gt;New studies sought but none found: 2/13/02&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 2/12/02&lt;/p&gt;&lt;p&gt;Reformatted: 7/20/01&lt;/p&gt;" NOTES_MODIFIED="2008-09-26 16:57:34 +0100" NOTES_MODIFIED_BY="Toby Lasserson">
<UP_TO_DATE>
<DATE DAY="17" MONTH="4" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="2" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="3" YEAR="2003"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2014-06-05 16:32:28 +0100" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-05 16:32:28 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="5" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>PLS title amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-06-05 16:32:19 +0100" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-05 16:32:19 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="26" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="4" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Pneumology Division, Universidade Federal de São Paulo</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Clinical Trial Meta-analysis Unit, Universidade Federal de São Paulo</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>FAPESP - São Paulo Foundation of Support for Research. Proc.: 96/12506-9</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Felix Ram received funding from The Netherlands Asthma Foundation</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-05 16:33:17 +0100" MODIFIED_BY="Emma J Welsh">
<SUMMARY MODIFIED="2014-06-05 16:33:17 +0100" MODIFIED_BY="Emma J Welsh">
<TITLE MODIFIED="2014-06-05 16:33:08 +0100" MODIFIED_BY="Emma J Welsh">Oral theophylline compared to placebo for people with chronic obstructive pulmonary disease (COPD)</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-05 16:33:17 +0100" MODIFIED_BY="Emma J Welsh">
<P>Theophylline treatment is commonly used in people with chronic obstructive pulmonary disease (COPD). This systematic review shows that orally administered theophylline improves lung function and levels of oxygen and carbon dioxide in the blood. However, there is limited data on its effect on symptoms, exercise capacity or quality of life. Despite being associated with increased side effects, particularly nausea, participants preferred theophylline over placebo.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Oral theophylline has, for many years, been used as a bronchodilator in patients with COPD. Despite the introduction of new drugs, and its narrow therapeutic index, theophylline is still recommended for COPD treatment. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effectiveness of oral theophylline when compared to placebo in patients with stable COPD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Airways Group trial register and Cochrane Central Register of Controlled Trials Cochrane Controlled Clinical Registers were searched. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All studies were randomised controlled trials (RCTs).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently abstracted data and asessed the methodological quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty RCTs met the inclusion criteria. Concomitant therapy varied from none to any other bronchodilator plus corticosteroid (oral and inhaled). The following outcomes were significantly different when compared to placebo. </P>
<P>Forced expiratory volume in one second (FEV1) improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (CI) 40 to 160 ml. Similarly for forced vital capacity (FVC): WMD 210 ml 95%CI 100 to 320. Two studies reported an improvement in maximum oxygen consumption (VO2 max); WMD 195 ml/min, 95%CI 113 to 278. At rest, arterial oxygen tension at rest (PaO2) and arterial carbon dioxide tension at rest (PaCO2) both improved with treatment (WMD 3.2 mm Hg; 95%CI 1.2 to 5.1, and WMD -2.4 mm Hg; 95%CI -3.5 to -1.2, respectively). Walking distance tests did not improve (four studies, Standardised Mean Difference 0.30, 95%CI -0.01 to 0.62), neither did Visual Analogue Score for breathlessness in two small studies (WMD 3.6, 95%CI -4.6 to 11.8). The Relative Risk (RR) of nausea was greater with theophylline (RR 7.7; 95%CI 1.5 to 39.9). However, patients' preference for theophylline was greater than that for placebo (RR 2.27; 95%CI 1.26 to 4.11). Very few participants withdrew from these studies for any reason.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Theophylline has a modest effect on FEV1 and FVC and slightly improves arterial blood gas tensions in moderate to severe COPD. These benefits were seen in participants receiving a variety of different concomitant therapies. Improvement in exercise performance depended on the method of testing. There was a very low dropout rate in the studies that could be included in this review, which suggests that recruited participants may have been known by the investigators to be theophylline tolerant . This may limit the generalisability of these studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Chronic obstructive pulmonary disease (COPD), by definition, is characterised by limited reversibility with bronchodilator therapy (<LINK REF="REF-Folgering-1994" TYPE="REFERENCE">Folgering 1994</LINK>; <LINK REF="REF-ATS-1995" TYPE="REFERENCE">ATS 1995</LINK>). Patients often have major limitations of physical activity, especially breathlessness during exercise. Oral theophylline is a bronchodilator that has been used for many years although sympathomimetic and inhaled anticholinergic agents are now used more often (<LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>). Despite this change in prescribing patterns, there is still a perception that theophylline confers additional benefit over that produced by the newer agents (<LINK REF="REF-Raguso-1996" TYPE="REFERENCE">Raguso 1996</LINK>). Traditional methods of assessing clinical benefit with theophylline have been based upon physiological measurements of airways function, but some studies have shown improvement in exercise performance, breathlessness and health status (quality of life) with minimal change in lung function (<LINK REF="STD-Vereen-1986" TYPE="STUDY">Vereen 1986</LINK>). </P>
<P>The major therapeutic benefit of theophylline has been attributed to its phosphodiesterase inhibitor activity, which inhibits the degradation of cyclic adenosine monophosphate (cAMP). Other mechanisms of action proposed for the action of theophylline include: inhibition of bronchoconstrictors (prostaglandins) as a result of the increased levels of cellular cAMP (<LINK REF="REF-Horrobin-1977" TYPE="REFERENCE">Horrobin 1977</LINK>); increased cellular calcium uptake and distribution involved in smooth muscle contraction (<LINK REF="REF-Aubier-1985" TYPE="REFERENCE">Aubier 1985</LINK>); increases in endogenous secretion of cortisol; stimulation of release of endogenous catecholamines (<LINK REF="REF-Atuk-1967" TYPE="REFERENCE">Atuk 1967</LINK>; <LINK REF="REF-Higbee-1982" TYPE="REFERENCE">Higbee 1982</LINK>); positive inotropic effect on the heart (<LINK REF="REF-Matthay-1986" TYPE="REFERENCE">Matthay 1986</LINK>) and theophylline is also known to be a mild diuretic (<LINK REF="REF-Johannesson-1985" TYPE="REFERENCE">Johannesson 1985</LINK>). Increased release of endogenous cortisol and catecholamines by theophylline may have a similar effect to that of the administration of corticosteroids (<LINK REF="REF-Mendella-1982" TYPE="REFERENCE">Mendella 1982</LINK>). </P>
<P>Theophylline is known to have a central effect on respiration. In COPD, xanthine derivatives can bring about acute and long-term enhancement of the hypoxemic ventilatory response (<LINK REF="REF-Aubier-1983" TYPE="REFERENCE">Aubier 1983</LINK>) by increasing inspiratory muscle drive, resulting in tidal volume increases (<LINK REF="REF-Spinelli-1991" TYPE="REFERENCE">Spinelli 1991</LINK>). </P>
<P>The role of theophylline in the management of COPD has not been fully defined. Studies have not consistently shown theophylline to be beneficial in the management of stable COPD (<LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>; <LINK REF="REF-Eaton-1980" TYPE="REFERENCE">Eaton 1980</LINK>; <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>). The <LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK> guidelines on management of COPD recommends use of xanthine derivatives as a last resort and only after all other treatments have failed to show a response. The ATS guidelines on COPD (<LINK REF="REF-ATS-1995" TYPE="REFERENCE">ATS 1995</LINK>) makes stronger recommendations for the use of theophylline in both stable and acute management of COPD but due to its narrow therapeutic index (<LINK REF="REF-Woodcock-1983" TYPE="REFERENCE">Woodcock 1983</LINK>) it also recommends cautious use. Due to the increasing numbers of guidelines on COPD management and the lack of evidence-based documentation, the US National Heart Lung and Blood Institute and the World Health Organisation have jointly developed evidence-based guidelines for the management of COPD (<LINK REF="REF-Pauwels-2000" TYPE="REFERENCE">Pauwels 2000</LINK>; <LINK REF="REF-Gomez-2002" TYPE="REFERENCE">Gomez 2002</LINK>). This project known as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) aims to produce guidelines that are applicable globally and are based on well-controlled clinical studies (where available) and not on consensus. However, the latter would be used where there was insufficient evidence. The current GOLD guideline recommends the use of theophylline as second line option since many studies have shown its bronchodilator effectiveness in COPD (web address: http://www.goldcopd.com). </P>
<P>A major disadvantage with this class of drugs is the incidence of adverse effects, particularly those involving the gastro-intestinal tract, even when the plasma level is within the therapeutic range. The evaluation of efficacy and the assessment of adverse effects are important factors to consider when dose titrating with theophylline preparations (<LINK REF="REF-Persson-1986" TYPE="REFERENCE">Persson 1986</LINK>). </P>
<P>Most studies have been performed on small number of patients with short duration. To our knowledge, there is no systematic review regarding theophylline in stable COPD. Owing to the differing recommendations from various COPD guidelines and to the different conclusions from the many clinical studies this systematic review of the literature was performed to assess the effect of theophylline in patients with stable COPD.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy of oral theophylline compared to placebo in patients with stable COPD.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All studies were randomised controlled trials which involved treatment with theophylline or placebo in patients with COPD. Studies of any duration were considered for inclusion but single dose studies were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies in patients with COPD were considered for inclusion. COPD was defined by internationally accepted criteria (e.g. <LINK REF="REF-ATS-1995" TYPE="REFERENCE">ATS 1995</LINK>; <LINK REF="REF-ERS-1995" TYPE="REFERENCE">ERS 1995</LINK>; <LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>) or defined objectively as a disorder characterised by reduced expiratory flow and slow forced emptying of the lungs and features which do not change markedly over several months (<LINK REF="REF-ERS-1995" TYPE="REFERENCE">ERS 1995</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The use of oral theophylline compared to placebo in a randomised fashion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>PRIMARY OUTCOMES MEASURES<BR/>(1) Exercise capacity: timed walking tests, endurance tests and incremental exercise tests on a treadmill or cycle ergometer.</P>
<P>(2) Lung function measurements (e.g. forced expiratory volume in one second (FEV1), forced vital capacity (FVC)).</P>
<P>(3) Health status (quality of life) scores: These include the Chronic Respiratory Disease Questionnaire (CRQ) or the St George's Respiratory Questionnaire (SGRQ).</P>
<P>SECONDARY OUTCOME MEASURES<BR/>(1) Arterial blood gas tensions (partial pressure oxygen (PaO2), partial pressure carbon dioxide (PaCO2)) and oxygen saturation (SaO2) on exercise and rest. </P>
<P>(2) Dyspnoea: measured directly at rest or during exercise, or indirectly by self report on symptom diaries (e.g. visual analogue scale, Borg scale or Likert scale or any other validated measurement).</P>
<P>(3) Participant preference for treatment</P>
<P>(4) Adverse effects: frequency of gastric effects (nausea, diarrhoea, mild abdominal discomfort), insomnia, and arrhythmia's (atrial fibrillation, tachycardia, ventricular extrasystole).</P>
<P>(5) Acute exacerbations</P>
<P>(6) Mortality: proportion of deaths </P>
<P>(7) Dropout rate: number of participants dropping out of the study.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We carried out a search of the Cochrane Airways Group trial register and the Cochrane Central Register of Controlled Trials using the following search strategy: obstructive OR bronchitis OR pulmonary emphysema OR bronchial hyperreactivity OR COPD OR COLD OR emphysema AND aminophylline OR theophylline OR theo* OR uniphyl OR nuelin. We also conducted separate and additional searches using MEDLINE (1966 to Feb 2002), EMBASE (1982 to Feb 2002), CINAHL (Feb 2002), and LILACS (1982 to Feb 2002) databases. We considered atudies of any duration or in any language. We identified other potential studies by writing to key authors, and examining the bibliographies of included studies and relevant review articles.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>LOCATING AND SELECTING STUDIES<BR/>Two reviewers (FR, SC) independently assessed the titles and abstracts of all reports of trials identified by electronic searching. The full text copies of all potential trials were obtained. Disagreements between reviewers were resolved with discussion.</P>
<P>STUDY QUALITY<BR/>Two reviewers independently assessed the methodological quality. We assessed all included studies using two study quality scales. The Cochrane assessment of allocation concealment was used, Grade A: Adequate concealment, Grade B: Uncertain about the method of allocation concealment, Grade C: Clearly inadequate allocation concealment &amp; Grade D: Allocation concealment not used. </P>
<P>In addition, we also graded studies using the five point <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK> study quality score: </P>
<P>Was the study described as randomised? Yes = 1; No = 0<BR/>Was the study described as double blind? Yes = 1; No = 0<BR/>Was there a description of the withdrawals and dropouts? Yes = 1; No = 0<BR/>Was the method of randomisation well described and appropriate? Yes = 1; No = 0<BR/>Was the method of double blinding well described and appropriate? Yes = 1; No = 0<BR/>Deduct one point if methods for randomisation or blinding were inappropriate.</P>
<P>STATISTICAL ANALYSIS <BR/>Where possible, we pooled trial outcome data. As planned in the protocol, for continuous variables, we calculated the results of individual studies as fixed effect weighted mean difference (WMD) or standardised mean difference (SMD) including the 95% confidence interval (CI) for each outcome. Where results were expressed as dichotomous variables, we calculated odds ratio (OR) or relative risks (RR) with 95% CI for individual outcomes. </P>
<P>The intention was to analyse separately trials employing a crossover design from those using a parallel-group design. If first-arm data from crossover trials was reported or if we had been able to obtain this data from the authors, then this would have been combined with data from parallel design trials. In the event, all trials were crossover in design, therefore aggregate means (from both study arms) were entered into RevMan and pooled.</P>
<P>SENSITIVITY ANALYSIS <BR/>For pooled effects, we carried out a test for heterogeneity; p &lt; 0.05 was considered statistically significant. If there was significant heterogeneity, we would have performed sensitivity tests using study quality, duration of study, dose and type of theophylline preparation and level of concomitant medication usage. When data were missing (in the case of SDs) these were calculated using the average of other trial SDs for that outcome. If range values were reported, SD was computed from the range using the following [SD = (UR - LR) / (2 x 1.96), 1.96 is for 95% range but changes to 1.64 and 2.58 for 90% and 99% reference ranges]. If only p values were reported, a pooled estimate of SD was computed by converting the p value to a Student's t-value; thereafter calculating SD using the following [SD = (square-root {n1 x n2} / {n1 + n2}) x (difference in means / t-value)]. Wherever these estimates of SDs were necessary, we conducted a sensitivity analysis of the overall result, excluding the calculated SDs, to test if the treatment effect differed significantly.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Please refer to the table "Characteristics of included studies" for detailed descriptions of each included study. A brief summary is provided below. </P>
<P>SEARCH FOR STUDIES<BR/>From 310 abstracts, we retrieved 86 full text papers for closer assessment. We selected twenty-four studies for inclusion. Four studies were multiple publications of the same cohort of participants. <LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK> had one follow-up publication, <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK> had two additional publications and the <LINK REF="STD-Iversen-1992" TYPE="STUDY">Iversen 1992</LINK> study had one duplicate publication. Therefore, there were 20 included studies (excluding four duplicate publications). The 62 excluded studies with their reasons for exclusion are listed in the table "Characteristics of excluded studies". </P>
<P>LOCATION OF STUDIES<BR/>Six studies were conducted in USA (<LINK REF="STD-Schmidt-1979" TYPE="STUDY">Schmidt 1979</LINK>; <LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>, <LINK REF="STD-Marvin-1983" TYPE="STUDY">Marvin 1983</LINK>; <LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>; <LINK REF="STD-Kongragunta-1988" TYPE="STUDY">Kongragunta 1988</LINK>), three in Canada (<LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>; <LINK REF="STD-Rivington-1988" TYPE="STUDY">Rivington 1988</LINK>; <LINK REF="STD-Thomas-1992" TYPE="STUDY">Thomas 1992</LINK>), two each in the UK (<LINK REF="STD-Anderson-1982" TYPE="STUDY">Anderson 1982</LINK>; <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>), Israel (<LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>), Ireland (<LINK REF="STD-Power-1992" TYPE="STUDY">Power 1992</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>) and Japan (<LINK REF="STD-Nishimura-1993" TYPE="STUDY">Nishimura 1993</LINK>; <LINK REF="STD-Nishimura-1995" TYPE="STUDY">Nishimura 1995</LINK>) and one each in Denmark (<LINK REF="STD-Iversen-1992" TYPE="STUDY">Iversen 1992</LINK>), France (<LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>) and Germany (<LINK REF="STD-Machraoui-1994" TYPE="STUDY">Machraoui 1994</LINK>). </P>
<P>TYPES OF PARTICIPANTS<BR/>All studies included adult participants with COPD defined using objective criteria of less than 15% in FEV1 reversibility after inhaling a bronchodilator in six studies (<LINK REF="STD-Schmidt-1979" TYPE="STUDY">Schmidt 1979</LINK>; <LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>; <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>; <LINK REF="STD-Power-1992" TYPE="STUDY">Power 1992</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>) or 25% in two studies (<LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>; <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>). The MRC definition of COPD was used in two studies (<LINK REF="STD-Anderson-1982" TYPE="STUDY">Anderson 1982</LINK>; <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>) and the ATS definition in one (<LINK REF="STD-Nishimura-1995" TYPE="STUDY">Nishimura 1995</LINK>). One study (<LINK REF="STD-Thomas-1992" TYPE="STUDY">Thomas 1992</LINK>) did not include participants who had a greater than 20% change in either FEV1 or FVC over the previous two years. Most of the studies also used a pre-defined criterion based on predicted FEV1 or FEV1/FVC ratio for including participants in their study, typical values for FEV1 were less than 60 to 70% and for FEV1/FVC ratio it was less than 0.6 to 0.7. One study (<LINK REF="STD-Nishimura-1995" TYPE="STUDY">Nishimura 1995</LINK>) included participants with a post-bronchodilator FEV1/FVC ratio of less than 70%. All of the studies included participants who were either ex or current smokers and excluded participants who had asthma. Baseline mean FEV1 for the participants in the 20 studies ranged from 0.96 to 1.15 L. Mean age ranged from 58 to 69 years.</P>
<P>COMMITTANT MEDICATION<BR/>Four of the studies did not allow use of bronchodilators during the study period (<LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>; <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>; <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>; <LINK REF="STD-Thomas-1992" TYPE="STUDY">Thomas 1992</LINK>). Twelve studies permitted use of regular bronchodilators and inhaled corticosteroids for the duration of the study (<LINK REF="STD-Anderson-1982" TYPE="STUDY">Anderson 1982</LINK>; <LINK REF="STD-Marvin-1983" TYPE="STUDY">Marvin 1983</LINK>; <LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>; <LINK REF="STD-Kongragunta-1988" TYPE="STUDY">Kongragunta 1988</LINK>; <LINK REF="STD-Rivington-1988" TYPE="STUDY">Rivington 1988</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>; <LINK REF="STD-Nishimura-1993" TYPE="STUDY">Nishimura 1993</LINK>; <LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Machraoui-1994" TYPE="STUDY">Machraoui 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>; <LINK REF="STD-Nishimura-1995" TYPE="STUDY">Nishimura 1995</LINK>). Four studies did not describe concomitant medication use (<LINK REF="STD-Schmidt-1979" TYPE="STUDY">Schmidt 1979</LINK>; <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>; <LINK REF="STD-Iversen-1992" TYPE="STUDY">Iversen 1992</LINK>; <LINK REF="STD-Power-1992" TYPE="STUDY">Power 1992</LINK>). <BR/>
<BR/>TYPES OF INTERVENTION<BR/>All 20 included studies were of crossover design and used dosing schedules to obtain plasma theophylline levels in the therapeutic range (10 to 20 mg/ml). Five studies used short acting or immediate release theophylline preparations (<LINK REF="STD-Schmidt-1979" TYPE="STUDY">Schmidt 1979</LINK>; <LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>; <LINK REF="STD-Marvin-1983" TYPE="STUDY">Marvin 1983</LINK>; <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>; <LINK REF="STD-Machraoui-1994" TYPE="STUDY">Machraoui 1994</LINK>) while the remaining 15 studies used long acting or sustained release theophylline preparations. Where studies have reported both pre and post-bronchodilator (e.g. salbutamol, terbutaline, ipratropium bromide) study measurements, only the pre-bronchodilator measurements were used (for the meta-analysis) as the purpose of this review was to observe the effects of oral theophylline administration and not to estimate the effects of immediate post-bronchodilator therapy. </P>
<P>The duration of the studies ranged from 7 to 90 days. The duration of each study was entered into RevMan (as days) under user defined category, in order to observe any influence of study duration on effect size. </P>
<P>Nine of the studies reported adequate washout periods between their crossover arms ranging from three days to two weeks (<LINK REF="STD-Anderson-1982" TYPE="STUDY">Anderson 1982</LINK>; <LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>; <LINK REF="STD-Kongragunta-1988" TYPE="STUDY">Kongragunta 1988</LINK>; <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>; <LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>; <LINK REF="STD-Machraoui-1994" TYPE="STUDY">Machraoui 1994</LINK>). The remaining 11 studies did not report any washout period. This, however, may not mean that no washout period was employed by these 11 studies. To date we have not received any correspondence from the authors to verify this information.</P>
<P>DROPOUT AND WITHDRAWALS<BR/>Only one study (<LINK REF="STD-Iversen-1992" TYPE="STUDY">Iversen 1992</LINK>) failed to report dropouts. In the others, with the exception of <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK> (eight withdrawals from 27 recruited) the dropout out rate was generally very low. Nine studies reported no dropouts (<LINK REF="STD-Marvin-1983" TYPE="STUDY">Marvin 1983</LINK>; <LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>; <LINK REF="STD-Rivington-1988" TYPE="STUDY">Rivington 1988</LINK>; <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>; <LINK REF="STD-Power-1992" TYPE="STUDY">Power 1992</LINK>; <LINK REF="STD-Nishimura-1993" TYPE="STUDY">Nishimura 1993</LINK>; <LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>There was total agreement between two reviewers on the inclusion of studies and for the quality scores. Four studies were graded as Cochrane 'A' (adequate allocation concealment) (<LINK REF="STD-Schmidt-1979" TYPE="STUDY">Schmidt 1979</LINK>; <LINK REF="STD-Marvin-1983" TYPE="STUDY">Marvin 1983</LINK>; <LINK REF="STD-Rivington-1988" TYPE="STUDY">Rivington 1988</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>), and the remaining 16 studies scored a 'B' grade (unclear allocation concealment). The mean (SD) score for Jadad study quality was 2.8 (0.81) and the range was 1 to 5. Most of the included studies (12) received a Jadad score of three, five studies received a score of two, and three studies each received a score of one, four and five. Overall the studies were of adequate quality as none of the studies scored 'C' with the Cochrane grading and the mean Jadad score was 2.8, which is considered of adequate-to-good quality. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>OUTCOMES REPORTED IN TWO OR MORE INCLUDED STUDIES: STATISTICALLY SIGNIFICANT EFFECT <BR/>FEV1 - L [Comparison 01:01:01]<BR/>Thirteen studies with 244 patients contributed data towards this outcome which showed a significant improvement of 100 ml with treatment (WMD 100 ml; 95%CI 40 to 160). One of the thirteen studies did not report any SD for FEV1 (<LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>) so it was estimated from the values reported for range. A sensitivity analysis without the <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK> study did not alter the mean overall result (WMD 110 ml; 95%CI 40 to 170) compared to when all 13 studies were included. There was no evidence of heterogeneity in this effect size across the studies.</P>
<P>FVC - L [Comparisons 01:02:01&amp; 01:02:02]<BR/>Eleven studies with 196 patients contributed data towards this outcome which showed significant improvement of 210 ml with treatment (WMD 210 ml; 95%CI 100 to 320). Two of the 11 studies did not report any SD's for FVC (<LINK REF="STD-Schmidt-1979" TYPE="STUDY">Schmidt 1979</LINK>; <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>) so they were estimated from the reported range and p values, respectively. A sensitivity analysis without the <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK> and <LINK REF="STD-Schmidt-1979" TYPE="STUDY">Schmidt 1979</LINK> studies did not alter the mean overall result (WMD 200 ml; 95%CI 70 to 320) compared to when all 11 studies were included. FVC reported as percent predicted by three studies was also significant (WMD 3.93; 95%CI 0.22 to 7.65).</P>
<P>VO2 max - ml/min [Comparison 01:09]<BR/>Two studies with 32 patients reported this outcome (<LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>) which showed significant improvement with treatment (WMD 195 ml/min; 95%CI 113 to 278).</P>
<P>PaO2 - mm Hg at rest [Comparison 01:10]<BR/>Six studies with 156 patients reported this outcome (<LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>; <LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>; <LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>) which showed significant improvement with treatment (WMD 3.18 mm Hg; 95%CI 1.23 to 5.13).</P>
<P>PaCO2 - mm Hg at rest [Comparison 01:11]<BR/>Six studies with 156 patients reported this outcome (<LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>; <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK>, <LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>, <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>; <LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>) which showed significant decrease with treatment (WMD -2.36 mm Hg; 95%CI -3.52 to -1.21).</P>
<P>Patient preference for theophylline or placebo [Comparison 01:21]<BR/>Two studies with a total of 50 (cross over) subjects (<LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>) reported that participants preferred theophylline to placebo (RR 2.27; 95%CI 1.26 to 4.11). </P>
<P>Nausea [Comparison 01:23]<BR/>Three studies reported data on nausea (<LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK>; <LINK REF="STD-Mulloy-1993" TYPE="STUDY">Mulloy 1993</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>). The risk of experiencing nausea when on treatment with theophylline was significantly increased (RR 7.67; 95%CI 1.47 to 39.94). </P>
<P>There did not appear to be any influence of study duration on outcome effect size (using user-defined category in Forest plots). </P>
<P>OUTCOMES REPORTED IN TWO OR MORE STUDIES: NO STATISTICALLY SIGNIFICANT EFFECT</P>
<P>Distance walked (m) [Comparison 01:23]<BR/>Two studies (58 patients) reported distance walked in six minutes (<LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>; <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>) and two (22 patients) the distance walked in 12 minutes (<LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>). In neither group of studies was the effect significant and when all four studies were combined using an SMD the effect was still not significant (SMD 0.30; 95%CI -0.01 to 0.62). The mean difference in the six-minute walk studies was 33 m which is not at the threshold of clinical significance.</P>
<P>Visual Analogue Scale (VAS) for breathlessness [Comparison 01:14]<BR/>Two studies (32 patients) reported this (<LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>; <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>), there was no effect.</P>
<P>Symptoms of wheeze and dyspnea [Comparison 01:18]<BR/>Two studies (21 patients) reported these (<LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>; <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>), there was no effect.</P>
<P>Exacerbations [Comparison 01:20]<BR/>Two studies (45 patients) reported these (<LINK REF="STD-Rivington-1988" TYPE="STUDY">Rivington 1988</LINK>; <LINK REF="STD-Nishimura-1995" TYPE="STUDY">Nishimura 1995</LINK>), there was no effect.</P>
<P>Drop outs <BR/>It was possible to compare drop out rates between treatment arms in only three studies totaling 74 patients (<LINK REF="STD-Anderson-1982" TYPE="STUDY">Anderson 1982</LINK>; <LINK REF="STD-Fink-1994" TYPE="STUDY">Fink 1994</LINK>; <LINK REF="STD-Newman-1994" TYPE="STUDY">Newman 1994</LINK>). There was no difference.<BR/>
<BR/>No data were available for health status and mortality. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This review has shown that administering oral theophylline for at least seven days, to partients with moderate to severe COPD improves lung function, ventilatory capacity and arterial blood gas tensions in patients with stable COPD. Participants preference for theophylline was greater than that for placebo. However, the number of adverse effects (nausea) was greater with theophylline treatment. </P>
<P>The magnitudes of the lung function changes are relatively small, but similar to those reported in another Cochrane review of long-acting beta2-agonists (<LINK REF="REF-Appleton-2002" TYPE="REFERENCE">Appleton 2002</LINK>). Meaningful symptomatic responses from bronchodilators in the presence of only trivial changes in FEV1 and FVC have been reported (<LINK REF="STD-Mahler-1985" TYPE="STUDY">Mahler 1985</LINK>; <LINK REF="REF-Wolkove-1989" TYPE="REFERENCE">Wolkove 1989</LINK>; <LINK REF="REF-Hay-1992" TYPE="REFERENCE">Hay 1992</LINK>). Unfortunately, there were very small numbers of studies reporting symptoms in this review. The included studies that attempted to measure improvements in symptoms (e.g. dyspnoea, quality of life, wheeze) all showed improvements, but, owing to minimal reporting and the use of different methodologies the data could not be collated meaningfully. Individual studies did, however, report benefits. <LINK REF="STD-Alexander-1980" TYPE="STUDY">Alexander 1980</LINK> used a six point scale which measured dyspnoea, wheezing, cough, sputum, walking and feelings that showed improvements in all categories with the use of theophylline. The study by <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK> reported significant improvements in dyspnoea and quality of life scores measures by CRQ. <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK> and <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK> reported a modest improvement in dyspnoea with theophylline treatment. <LINK REF="STD-Iversen-1992" TYPE="STUDY">Iversen 1992</LINK> reported significant improvements in dyspnoea scores during theophylline treatment. <LINK REF="STD-Marvin-1983" TYPE="STUDY">Marvin 1983</LINK> and <LINK REF="STD-Thomas-1992" TYPE="STUDY">Thomas 1992</LINK> reported improvements in both wheezing and shortness of breath with theophylline. </P>
<P>Other mechanisms have been proposed to explain how theophylline could improve symptoms or reduce breathlessness in partients with COPD. The <LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK> study measured the effects of theophylline on 33 participants with stable COPD. In their study a dose of theophylline that resulted in serum concentrations of 15-20 mg/L, only led to an increase in FEV1 of 13% (130 mls) but there was a significant 64% decrease in trapped gas volume (1.84 L to 0.67 L ). Unfortunately, this was the only study to report data on trapped gas volume in this review. </P>
<P>Other workers have shown that inhaled beta 2-agonists and ipratropium bromide reduce exertional breathlessness in subjects with stable COPD and this correlates strongly with decreases in thoracic gas entrapment (<LINK REF="STD-Chrystyn-1988" TYPE="STUDY">Chrystyn 1988</LINK>; <LINK REF="REF-Webb-1990" TYPE="REFERENCE">Webb 1990</LINK>) and dynamic hyperinflation (<LINK REF="REF-Belman-1996" TYPE="REFERENCE">Belman 1996</LINK>; <LINK REF="REF-O_x0027_Donnell-1999" TYPE="REFERENCE">O'Donnell 1999</LINK>). The improvements in lung function seen with theophylline in this review may be due to dilatation of the small airways with a consequent reduction in gas trapping. A fall in trapped gas volume (and thus FRC) is likely to improve the mechanical advantage of the diaphragm and chest wall muscles and may well explain many of the reported effects of theophylline on the respiratory muscles (<LINK REF="REF-Murciano-1984" TYPE="REFERENCE">Murciano 1984</LINK>). </P>
<P>Theophylline has also been demonstrated to increase the pressure generated by respiratory muscles (<LINK REF="STD-Umut-1992" TYPE="STUDY">Umut 1992</LINK>) and increase diaphragmatic strength (<LINK REF="STD-Kongragunta-1988" TYPE="STUDY">Kongragunta 1988</LINK>). Its effect has been shown to be greater in fatigued diaphragm (<LINK REF="REF-Murciano-1984" TYPE="REFERENCE">Murciano 1984</LINK>) as has been shown in severe COPD. In one study, theophylline increased trans-diaphragmatic pressure by 16% and this increase persisted even after 30 days of treatment with theophylline (<LINK REF="REF-Murciano-1984" TYPE="REFERENCE">Murciano 1984</LINK>). In therapeutic doses theophylline is also known to increase respiratory drive independent of its effect on lung function (<LINK REF="STD-Ashutosh-1997" TYPE="STUDY">Ashutosh 1997</LINK>). It is also known to increase respiratory muscle function in normal participants (<LINK REF="REF-Sherman-1996" TYPE="REFERENCE">Sherman 1996</LINK>) and in COPD (<LINK REF="STD-Umut-1992" TYPE="STUDY">Umut 1992</LINK>) as measured by increases in maximal inspiratory and expiratory pressures. It has also been suggested that theophylline reduces breathlessness by improving diaphragmatic contractility. The <LINK REF="STD-Murciano-1989" TYPE="STUDY">Murciano 1989</LINK> trial demonstrated an improvement in respiratory muscle performance as indicated by a decline in the ratio of inspiratory pleural pressure during quiet breathing to the maximal pleural pressure (data not reported in this review as an outcome). </P>
<P>Another interpretation is that the improvement in respiratory muscle function is due not to an increase in diaphragmatic contractility but to an improvement in the length-tension relationship of the diaphragm. This is because there is a reduction in gas trapping and a recent study by <LINK REF="REF-Hatipoglu-1999" TYPE="REFERENCE">Hatipoglu 1999</LINK> supports this interpretation. It is possible and likely that these effects of theophylline had a role in slightly but significantly improving lung function as has been shown by this review.</P>
<P>There were small but statistically significant improvements in arterial blood gas tensions in patients treated with theophylline. In severe cases of COPD, respiratory rate is increased, and this may be combined with shallow breathing that is pronounced by carbon dioxide retention. It is known that theophylline improves minute ventilation in humans (<LINK REF="REF-Darnall_x002d_Jr-1985" TYPE="REFERENCE">Darnall-Jr 1985</LINK>) and animals (<LINK REF="REF-Javaheri-1989" TYPE="REFERENCE">Javaheri 1989</LINK>) and also alters the ventilatory response in COPD seen as improved ventilatory capacity measured as increased VO2 max. This ventilatory response results in an increase in tidal volume, which may be responsible for the improvement seen in blood gas tensions. Both these changes (increase in VO2 max and improved blood gas tensions) could be related to either a direct positive inotropic effect of theophylline on the respiratory muscles (<LINK REF="REF-Okubo-1987" TYPE="REFERENCE">Okubo 1987</LINK>; <LINK REF="STD-Kongragunta-1988" TYPE="STUDY">Kongragunta 1988</LINK>; <LINK REF="REF-Landsberg-1990" TYPE="REFERENCE">Landsberg 1990</LINK>; <LINK REF="REF-Marsh-1993" TYPE="REFERENCE">Marsh 1993</LINK>) or due to its action via a central stimulatory pathway (<LINK REF="REF-Cooper-1987" TYPE="REFERENCE">Cooper 1987</LINK>; <LINK REF="REF-Javaheri-1990" TYPE="REFERENCE">Javaheri 1990</LINK>) or both. It is known that theophylline is capable of stimulating the medullary respiratory center (<LINK REF="REF-Ritchie-1975" TYPE="REFERENCE">Ritchie 1975</LINK>). </P>
<P>Although only two studies provided data for VO2 max, this is an important significant finding as greater exercise performance is implied by increases in VO2 max. Unfortunately there were not enough studies providing data on exercise performance (distance walked, cycle endurance or progressive cycle ergometry) to permit us to relate the increase in VO2 max to exercise performance. The effect size in the two studies that reported it was approximately 30 metres for a six minute walk which is not clinically significant.</P>
<P>Theophylline has a narrow therapeutic index and adverse effects are common even when the serum concentrations are in the 'therapeutic range' of 10 to 20 mg/L. In this review, nausea was reported by significantly more participants treated with theophylline compared with placebo. Another more serious adverse effect of theophylline in patients with COPD, is supraventricular arrhythmias (<LINK REF="REF-Levine-1985" TYPE="REFERENCE">Levine 1985</LINK>; <LINK REF="REF-Varriale-1993" TYPE="REFERENCE">Varriale 1993</LINK>), however, this was not reported in this review. Nevertheless, the benefits of theophylline in stable COPD have to be weighed against the risk of adverse effects. All of the included studies in this review aimed for theophylline concentrations within the therapeutic range. In patients with asthma theophylline exerts beneficial effects at serum concentrations lower than the traditional therapeutic range of 10 to 20 mg/L (<LINK REF="REF-Mitenko-1973" TYPE="REFERENCE">Mitenko 1973</LINK>; <LINK REF="REF-Evans-1997" TYPE="REFERENCE">Evans 1997</LINK>). Lower concentrations of theophylline have the advantage that they are associated with fewer adverse effects. In future studies of theophylline for stable COPD it may be appropriate to have a lower target concentration of theophylline. An alternative approach would be to study specific inhibitors of type IV phosphodiesterases such as Airflo® that are reported to be effective in the treatment of asthma but which have fewer adverse effects compared to theophylline (<LINK REF="REF-Compton-2000" TYPE="REFERENCE">Compton 2000</LINK>; <LINK REF="REF-Barnette-2000" TYPE="REFERENCE">Barnette 2000</LINK>; <LINK REF="REF-Giembycz-2000" TYPE="REFERENCE">Giembycz 2000</LINK>). </P>
<P>A possible pitfall of crossover studies, such as those included in this review, is the presence of carry-over effects of the first treatment into the second treatment period, leading to an underestimation of the real difference among treatments (<LINK REF="REF-Cleophas-1993" TYPE="REFERENCE">Cleophas 1993</LINK>). Nine of the studies reported adequate washout periods between their crossover arms ranging from three days to two weeks. The remaining 11 studies did not either have a washout period or failed to report any washout period. To date we have not received any correspondence from the authors to verify this information. </P>
<P>A second possible pitfall associated with crossover designs, is that the software we used (RevMan) forces us to analyse crossover studies as if they were parallel studies. It is known (<LINK REF="REF-Cleophas-1996" TYPE="REFERENCE">Cleophas 1996</LINK>) that the two methods give identical results if the response to the two treatments, in the same individual, is completely unrelated. However, parallel analysis may lead to decreased statistical power when compared to paired analysis, if the response to the two treatments is positively correlated (i.e. if patients improving during bronchodilator are also more likely to improve somewhat during placebo). This possibility cannot be discounted in our review. The results of the statistical analysis from two-period crossover trials make two main assumptions, no period effect and no treatment-period interaction. But none of the authors reported these findings (correlation between the responses to the two treatments) from their studies and the presentation of the data did not permit these types of analysis. Therefore, we cannot exclude that our analysis underestimated the statistical significance of the observed differences, as compared to a paired analysis.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Theophyllines produce a small improvement in FEV1 that is similar in size to that reported for long acting beta2-agonists in COPD patients, with and without adjuvant bronchodilator therapy. There also appears to be a small mean improvement in arterial blood gas tensions. The evidence for symptomatic benefit or improved exercise performance is less consistent. There is an increased incidence of nausea, but on average, the patients in the studies reviewed here preferred theophylline. The tolerance of theophylline in the patients recruited to these studies (as reflected by the absence of an increased drop out rate) is a little surprising since clinical experience suggests that a significant number of patients cannot tolerate the gastro-intestinal side-effects. We conclude that, with close monitoring of individual patients and their serum theophylline levels, it appears that beneficial effects may be obtained in those who remain symptomatic from COPD despite first-line bronchodilator therapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Larger parallel randomised controlled trials with explicit clinical and diagnostic criteria, sufficient duration of follow-up and description of all relevant clinical outcome measures appear warranted. Many previously conducted studies have relied heavily on the readily available physiological tests (e.g. FEV1, FVC, PEFR). As these are not particularly sensitive measures of change in this group of patients (<LINK REF="REF-Wolkove-1989" TYPE="REFERENCE">Wolkove 1989</LINK>; <LINK REF="REF-Celli-2000" TYPE="REFERENCE">Celli 2000</LINK>) we suggest that other relevant outcome measures should be used (e.g. symptoms, health status, adverse effects, exercise capacity &amp; endurance, length of hospital stay, incidence of exacerbations, health care utilisation and cost effectiveness). Future studies should also endeavour to define which 'types' of patients are most likely to respond to treatment with theophylline. Studies also need to examine the role of theophylline in comparison, and in conjunction, with newer agents such as long acting bronchodilators. Further investigation of the effect of theophylline on ventilatory mechanics would be helpful to delineate the non-bronchodilator effects of theophylline, which appear important. Because of a lower incidence of adverse effects, it will be interesting to observe the efficacy of specific inhibitors of type IV phosphodiesterases in people with COPD. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The author's would like to thank the members of the Cochrane Airways Group based at St George's Hospital Medical School, University of London and Kirsty Olsen who has copy edited this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>There are no known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>List includes: Ram FSF (FR), Jones PW (PJ), Castro AA (AAC), de Brito Jardim JR (JRJ), Atallah AN (ANA), Lacasse Y (YL), Mazzini R (RM), Goldstein R (RG), Cendon S (SC).</P>
<P>Proposing the idea of the review: PJ<BR/>Designing the review: SC, AAC<BR/>Coordinating the review: FR, SC<BR/>Data collection for the review: FR, SC, AAC, RM<BR/> Developing search strategy: FR, AAC<BR/> Undertaking searches: FR, AAC<BR/> Screening search results: AAC, FR<BR/> Organising retrieval of papers: FR, SC<BR/> Screening retrieved papers against inclusion criteria: FR, SC, AAC<BR/> Appraising quality of papers: FR, SC, AAC<BR/> Abstracting data from papers: FR, SC, AAC, RM<BR/> Writing to authors of papers for additional information: FR<BR/> Obtaining and screening data on unpublished studies: FR<BR/>Data management for the review: FR, SC, AAC<BR/> Entering data into RevMan: FR, SC, AAC, RM<BR/>Analysis of data: FR, SC<BR/>Interpretation of data: FR, SC<BR/> Providing a methodological perspective: FR, SC, AAC<BR/> Providing a clinical perspective: FR, SC, AAC<BR/> Providing a policy perspective: FR, SC, AAC<BR/> Providing a consumer perspective: FR, SC, AAC<BR/>Writing the review: FR<BR/>Responsible for future updates of the review: FR</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-1980" NAME="Alexander 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Alexander M, Dull W, Kasik J. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. Jama 1980;244:2286-90.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alexander M, Dull W, Kasik J</AU>
<TI>Treatment of chronic obstructive pulmonary disease with orally administered theophylline</TI>
<SO>The Journal of the American Medical Association</SO>
<YR>1980</YR>
<VL>244</VL>
<PG>2286-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dull WL, Alexander MR, Sadoul P, Woolson RF</AU>
<TI>The efficacy of isoproterenol inhalation for predicting the response to orally administered theophylline in chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1982</YR>
<VL>126</VL>
<NO>4</NO>
<PG>656-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1982" NAME="Anderson 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson G, Peel ET, Pardoe T, Jones R</AU>
<TI>Sustained-release theophylline in chronic bronchitis</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1982</YR>
<VL>76</VL>
<NO>3</NO>
<PG>261-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrystyn-1988" NAME="Chrystyn 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. British Med J 1988;297:1506-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrystyn H, Mulley BA, Peake MD</AU>
<TI>Dose response relation to oral theophylline in severe chronic obstructive airways disease</TI>
<SO>British Medical Journal</SO>
<YR>1988</YR>
<VL>297</VL>
<PG>1506-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dullinger-1986" NAME="Dullinger 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dullinger D, Kronenberg R, Niewoehner DE</AU>
<TI>Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction</TI>
<SO>Chest</SO>
<YR>1986</YR>
<VL>89</VL>
<NO>2</NO>
<PG>171-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fink-1994" NAME="Fink 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Fink G, Kaye C, Sulkes J, Gabbay U, Spitzer SA. Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease. Thorax 1994; 49:332-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fink G, Kaye C, Sulkes J, Gabbay U, Spitzer SA</AU>
<TI>Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>1994</YR>
<VL>49</VL>
<PG>332-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guyatt-1987" NAME="Guyatt 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Townsend M, Keller JL, Singer J</AU>
<TI>Should study subjects see their previous responses: data from a randomized control trial</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1989</YR>
<VL>42</VL>
<PG>913-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT</AU>
<TI>Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1988</YR>
<VL>148</VL>
<PG>1949-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhouse MT. Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Resp Dis 1987;135:1069-1074.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, et al</AU>
<TI>Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity, and quality of life</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1987</YR>
<VL>135</VL>
<PG>1069-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iversen-1992" NAME="Iversen 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;1999 address of author: Department of Pulmonary Medicine, Bispebjerg Hospital, DK 2400, Copenhagen NV, DENMARK&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Iversen E, Maltbaek N, Toennesen, Eiken P, Nielsen L, Laursen LC, et al</AU>
<TI>Sustained-release theophylline treatment of patients with irreversible chronic obstructive pulmonary disease</TI>
<SO>European Respiratory Journal</SO>
<YR>1992</YR>
<VL>5 Suppl (15)</VL>
<PG>137</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iversen ET, Eiken PA, Nielsen LM, Laursen LC, Maltbaek N, Tonnesen FV, et al</AU>
<TI>Theophylline treatment of irreversible, chronic obstructive pulmonary disease</TI>
<TO>Article in Danish</TO>
<SO>Ugeskr Laeger</SO>
<YR>1994</YR>
<VL>156</VL>
<NO>39</NO>
<PG>5696-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 7985256"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kongragunta-1988" NAME="Kongragunta 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Kongragunta VR, Druz WS, Sharp JT. Dyspnea and diaphragmatic fatigue in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 137: 662-667.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kongragunta VR, Druz WS, Sharp JT</AU>
<TI>Dyspnea and diaphragmatic fatigue in patients with chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1988</YR>
<VL>137</VL>
<PG>662-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Machraoui-1994" NAME="Machraoui 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Machraqui A; Lawo T; Schmidt EW; Hoffarth HP; Barmeyer J; Ulmer WT. Theophyllin bei ventrikul&amp;#228;ren rhythmusst&amp;#246;rungen. Atemwegs und Lungenkrankenheiten 1994;20: 510-514.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Machraoui A, Lawo T, Schmidt EW, Hoffarth HP, Barmeyer J, Ulmer WT</AU>
<TI>Ventricular arrythmias in chronic obstructive lung disease (COLD): effect of theophylline in therapeutic doses</TI>
<TO>Theophyllin bei ventrikulären rhythmusstörungen</TO>
<SO>Atemwegs und Lungenkrankenheiten</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>9</NO>
<PG>510-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahler-1985" NAME="Mahler 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985;131:22-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J</AU>
<TI>Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1985</YR>
<VL>131</VL>
<PG>22-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marvin-1983" NAME="Marvin 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Marvin PM, Baker BJ, Dutt AK, Murphy ML, Bone RC. Physiologic effects of oral bronchodilators during rest and exercise in chronic obstructive pulmonary disease. Chest 1983; 84: 684-689.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marvin PM, Baker BJ, Dutt AK, Murphy ML, Bone RC</AU>
<TI>Physiologic effects of oral bronchodilators during rest and exercise in chronic obstructive pulmonary disease</TI>
<SO>Chest</SO>
<YR>1983</YR>
<VL>84</VL>
<PG>684-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulloy-1993" NAME="Mulloy 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1030-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulloy E, McNicholas WT</AU>
<TI>Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1993</YR>
<VL>148</VL>
<PG>1030-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murciano-1989" NAME="Murciano 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Murciano D, Auclair M, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989;320: 1521-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murciano D, Auclair M, Pariente R, Aubier M</AU>
<TI>A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<NO>23</NO>
<PG>1521-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newman-1994" NAME="Newman 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Newman D, Tamir J, Speed L, Newman J, Ben-Dov I. Physiological and neuropsychological effects of theophylline in chronic obstructive pulmonary disease. Isr J Med Sci 1994; 30:811-16.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newman D, Tamir J, Speed L, Newman J, Ben-Dov I</AU>
<TI>Physiological and neuropsychological effects of theophylline in chronic obstructive pulmonary disease</TI>
<SO>Israel Journal of Medical Sciences</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>811-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishimura-1993" NAME="Nishimura 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishimura K, Koyama H, Ikeda A, Izumi T</AU>
<TI>Is oral theophylline effective in combination with both inhaled anticholinergic agent and inhaled beta 2-agonist in the treatment of stable COPD</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<NO>1</NO>
<PG>179-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 8325065"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishimura-1995" NAME="Nishimura 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T.  The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995;107:718-23.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T</AU>
<TI>The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>107</VL>
<NO>3</NO>
<PG>718-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Power-1992" NAME="Power 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Power CK, Morris AM, Sreenan SK, Burke CM</AU>
<TI>An assessment of oral theophylline in patients with "reversible" chronic obstructive pulmonary disease</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1992</YR>
<VL>161</VL>
<NO>5</NO>
<PG>509</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rivington-1988" NAME="Rivington 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rivington RN, Calcutt L, Hodder RV, Stewart JH, Aitken TTL</AU>
<TI>Safety and efficacy of once-daily Uniphyl tablets compared with twice-daily Theo-Dur tablets in elderly patients with chronic airflow obstruction</TI>
<SO>American Journal of Medicine</SO>
<YR>1988</YR>
<VL>85</VL>
<NO>1B</NO>
<PG>48-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1979" NAME="Schmidt 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Schmidt R, Altschuler S. The usefulness of theophylline in nonasthmatic airway obstruction. Angiology 1979;744-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt R, Altschuler S</AU>
<TI>The usefulness of theophylline in nonasthmatic airway obstruction</TI>
<SO>Angiology</SO>
<YR>1979</YR>
<VL>30</VL>
<NO>11</NO>
<PG>744-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-1992" NAME="Thomas 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Thomas P, Pugsley JA, Stewart JH. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest 1992; 101:160-65.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas P, Pugsley JA, Stewart JH</AU>
<TI>Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>101</VL>
<NO>1</NO>
<PG>160-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Adelroth-1998" NAME="Adelroth 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adelroth E, Barnes NC, Chung KF, Davies RJ, Poulter LW</AU>
<TI>Drug trials</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<VL>26 Suppl</VL>
<PG>36-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 9585879"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnold-1990" NAME="Arnold 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnold JD, Courtenay-Evans RJ, Whitfield RR, O'Reilly JF, Petrie GR, Higgins AJ, et al</AU>
<TI>Comparative assessment of enprofylline and theophylline for chronic obstructive airways disease in the elderly</TI>
<SO>Respiratory Medicine</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>3</NO>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ashutosh-1997" NAME="Ashutosh 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ashutosh K, Mohammad S, Fragale-Jackson J. Effects of theophylline on respiratory drive in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 1997; 37:1100-1107.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ashutosh K, Mohammad S, Fragale-Jackson J</AU>
<TI>Effects of theophylline on respiratory drive in patients with chronic obstructive pulmonary disease</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>37</VL>
<PG>1100-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bachmann-1995" NAME="Bachmann 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, et al</AU>
<TI>Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>5</NO>
<PG>529-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berry-1991" NAME="Berry 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Berry RB, Desa MM, Branum JP, Light RW. Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991 Feb;143(2):245-50&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berry RB, Desa MM, Branum JP, Light RW</AU>
<TI>Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1991</YR>
<VL>143</VL>
<NO>2</NO>
<PG>245-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beulcke-1995" NAME="Beulcke 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beulcke G</AU>
<TI>Acebrophylline and theophylline in the treatment of bronchial asthma. An open comparative, randomized study</TI>
<SO>Acta Therapeutica</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>2</NO>
<PG>101-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bleecker-1991" NAME="Bleecker 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Bleecker E, Britt EJ. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991;91:24S-7S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleecker E, Britt EJ</AU>
<TI>Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Medicine</SO>
<YR>1991</YR>
<VL>91Suppl</VL>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blom-1985" NAME="Blom 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blom BB, Boe J, Bulow K, Hagelqvist I</AU>
<TI>A comparison of oral betasub 2-agonist clenbuterol and salbutamol in obstructive lung disease</TI>
<SO>Currant Therapeutic Research, Clinical and Experimental</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>1</NO>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boos-1989" NAME="Boos 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boos R, van Kampen C, Weede W, Beck W</AU>
<TI>Nedocromil sodium therapy in asthma patients. Therapeutic effect in addition to treatment with oral theophylline and inhaled bronchodilator agents</TI>
<TO>In German</TO>
<SO>Fortschritte Der Medizin</SO>
<YR>1989</YR>
<VL>107</VL>
<NO>33</NO>
<PG>712-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carvalho_x002d_Pinto-1991" NAME="Carvalho-Pinto 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carvalho-Pinto RM, Terra Filho M, Cukier A</AU>
<TI>Influence of the combination of theophylline and beta 2 agonists by oral route on pulmonary funtion of patients with chronic obstructive lung disease</TI>
<SO>Revista Do Hospital Das Clinicas; Faculdade De Medicina Da Universidade De Sao Paulo</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>4</NO>
<PG>166-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chapman-1990" NAME="Chapman 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chapman KR, Boucher S, Hyland RH, Day A, Kreisman H, Rivington RR, et al</AU>
<TI>A comparison of enprofylline and theophylline in the maintenance therapy of chronic reversible obstructive airway disease</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1990</YR>
<VL>85</VL>
<NO>2</NO>
<PG>514-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conradson-1987" NAME="Conradson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conradson TB, Eklundh G, Olofsson B, Pahlm O, Persson G</AU>
<TI>Arrhythmogenicity from combined bronchodilator therapy in patients with obstructive lung disease and concomitant ischemic heart disease</TI>
<SO>Chest</SO>
<YR>1987</YR>
<VL>91</VL>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crimi-1995" NAME="Crimi 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crimi E, Orefice U, De Benedetto F, Grassi V, Brusasco V</AU>
<TI>Nedocromil sodium versus theophylline in the treatment of reversible obstructive airway disease</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1995</YR>
<VL>74</VL>
<NO>6</NO>
<PG>501-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cusack-1986" NAME="Cusack 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cusack BJ, Crowley JJ, Mercer GD, Charan NB, Vestal RE</AU>
<TI>Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia</TI>
<SO>American Review of Respiratory Diseases</SO>
<YR>1986</YR>
<VL>133</VL>
<NO>6</NO>
<PG>1110-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Lorenzo-1998" NAME="Di Lorenzo 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Lorenzo G, Morici G, Drago A, Pellitteri M E, Mansueto P, Melluso M, et al</AU>
<TI>Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease</TI>
<SO>Clinical Therapeutics</SO>
<YR>1998</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1130-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dini-2001" NAME="Dini 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dini FL, Cogo R</AU>
<TI>Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>4</NO>
<PG>258-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorow-1978" NAME="Dorow 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Dorow VP. Die wirkung oralen aminophyllin-praparates mit retardwirkung auf die atemwegswiderstande und arteriellen blutgase bei obstruktiven atemwegserkrankungen. Arzneim Forsch Drug Res 1978;28: 853-57.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorow V P</AU>
<TI>The effect of an oral aminophylline compound with protracted activity on respiratory resistance and blood gases in obstructive respiratory diseases</TI>
<TO>Die Wirkung eines oralen Aminophyllin-Praparates mit Retardwirkung auf die Atemwegswiderstande und arteriellen Blutgase bei obstruktiven Atemwegserkrankungen</TO>
<SO>Arzneim Forsch Drug Res</SO>
<YR>1978</YR>
<VL>28</VL>
<NO>1</NO>
<PG>853-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dull-1981" NAME="Dull 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Dull WL, Alexander MR, Kasik JE. Isoproterenol challenge during placebo and oral theophylline therapy in chronic obstructive pulmonary disease. Am Rev Respir Dis 1981; 123:340-342.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dull WL, Alexander MR, Kasik JE</AU>
<TI>Isoproterenol challenge during placebo and oral theophylline therapy in chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1981</YR>
<VL>123</VL>
<PG>340-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1984" NAME="Evans 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans W V</AU>
<TI>Plasma theophylline concentrations, six minute walking distances, and breathlessness in patients with chronic airflow obstruction</TI>
<SO>British Medical Journal</SO>
<YR>1984</YR>
<VL>289</VL>
<PG>1649-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzpatrick-1992" NAME="Fitzpatrick 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Fitzpatrick MF, Engleman HM, Boellert F, Mchardy R, Shapiro CM, Deary IJ, Douglas NJ. Effect of therapeutic theophylline levels on the sleep quality and daytime cognitive performance of normal subjects. Am Rev Respir Dis 1992; 145:1355-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzpatrick MF, Engleman HM, Boellert F, Mchardy R, Shapiro CM, Deary IJ, et al</AU>
<TI>Effect of therapeutic theophylline levels on the sleep quality and daytime cognitive performance of normal subjects</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>145</VL>
<PG>1355-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greening-1981" NAME="Greening 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greening A P, Baillie E, Gribbin H R, Pride N B</AU>
<TI>Sustained release oral aminophylline in patients with airflow obstruction</TI>
<SO>Thorax</SO>
<YR>1981</YR>
<VL>36</VL>
<NO>4</NO>
<PG>303-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harkaway-1985" NAME="Harkaway 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harkaway PS, Conlon PF, Hirsh JD, Allen WT</AU>
<TI>Comparison of two sustained-release theophylline preparations in adult paitents with obstructive airways disease</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1985</YR>
<VL>25</VL>
<NO>6</NO>
<PG>444-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horiguchi-1999" NAME="Horiguchi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiguchi T, Tachikawa S, Kasahara J, Doi M, Shiga M, Miyazaki J, et al</AU>
<TI>Suppression of airway inflammation by theophylline in adult bronchial asthma</TI>
<SO>Respiration</SO>
<YR>1999</YR>
<VL>66</VL>
<NO>2</NO>
<PG>124-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hudson-1973" NAME="Hudson 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hudson LD, Tyler ML, Petty TTL</AU>
<TI>Oral aminophylline and dikydroxypropyl theophylline in reversible obstructive airway disease: a single-dose, double blind, crossover comparison</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>7</NO>
<PG>367-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Javaheri-1996" NAME="Javaheri 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Javaheri S, Parker TJ, Wexler L, Liming JD, Lindower P, Roselle GA. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med 1996; 335:562-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Javaheri S, Parker TJ, Wexler L, Liming JD, Lindower P, Roselle GA</AU>
<TI>Effect of theophylline on sleep-disordered breathing in heart failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<PG>562-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karpel-1994" NAME="Karpel 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled B-agonist, and the combination of all three in patients with COPD. Chest 1994;105:1089-94.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W</AU>
<TI>A comparison of inhaled ipratropium, oral theophylline plus inhaled B-agonist, and the combination of all three in patients with COPD</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<NO>4</NO>
<PG>1089-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamont-1982" NAME="Lamont 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamont H, van der Straeten M, Pauwels R, Moerman E</AU>
<TI>The combined effect of theophylline and terbutaline in patients with chronic obstructive airway disease</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1982</YR>
<VL>63</VL>
<NO>1</NO>
<PG>13-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefcoe-1982" NAME="Lefcoe 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lefcoe NM, Toogood JH, Blennerhassett G, Baskerville J, Paterson NAM</AU>
<TI>The addition of an aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis</TI>
<SO>Chest</SO>
<YR>1982</YR>
<VL>82</VL>
<PG>300-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leitch-1981" NAME="Leitch 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leitch AG, Morgan A, Ellis DA, Bell G, Haslett C, McHardy GJR</AU>
<TI>Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis</TI>
<SO>Thorax</SO>
<YR>1981</YR>
<VL>36</VL>
<PG>787-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leuenberger-1997" NAME="Leuenberger 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Leuenberger P, Anderhub HP, Brandli O, Keller R, Knoblauch A, Kuhn M, Perruchoud AP, Rochat T, Russi E, Villiger B, Zellweger JP. Management 1997 of chronic obstructive pulmonary disease. Schweiz Med Wochenschr 1997;127: 766-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leuenberger P, Anderhub HP, Brandli O, Keller R, Knoblauch A, Kuhn M, et al</AU>
<TI>Management 1997 of chronic obstructive pulmonary disease</TI>
<SO>Schweiz Med Wochenschr</SO>
<YR>1997</YR>
<VL>127</VL>
<PG>766-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lunell-1983" NAME="Lunell 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lunell E, Svedmyr N, Andersson KE, Persson CG</AU>
<TI>A novel bronchodilator xanthine apparently without adenosine receptor antagonism and tremorogenic effect</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>64</VL>
<NO>5</NO>
<PG>333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahon-1999" NAME="Mahon 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Mahon JL, Laupacis A, Hodder R, McKim D, Paterson NAM, Wood TE, Donner A. Theophylline for irreversible chronic airflow limitation. Chest 1999; 115: 38-48.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahon JL, Laupacis A, Hodder R, McKim D, Paterson NAM, Wood TE, et al</AU>
<TI>Theophylline for irreversible chronic airflow limitation</TI>
<SO>Chest</SO>
<YR>1999</YR>
<VL>115</VL>
<PG>38-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Man-1996" NAME="Man 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Man GC, Chapman KR, Habib AS, Darke AC</AU>
<TI>Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>3</NO>
<PG>648-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marlin-1978" NAME="Marlin 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marlin GE, Hartnett BJ, Berend N, Hacket NB</AU>
<TI>Assessment of combined oral theophylline and inhaled beta adrenoceptor agonist bronchodilator therapy</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1978</YR>
<VL>5</VL>
<NO>1</NO>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1992" NAME="Martin 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin RJ, Pak J</AU>
<TI>Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>145</VL>
<NO>3</NO>
<PG>540-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McHardy-1981" NAME="McHardy 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHardy GJ, Morgan A, Ellis DA, Haslett C, Leitch AG</AU>
<TI>Physical effort capacity after administration of salbutamol or aminophylline</TI>
<TO>Physische belastbarkeit nach gabe von salbutamol- und phyllocontin- tabletten</TO>
<SO>Therapiewoche</SO>
<YR>1981</YR>
<VL>31</VL>
<PG>5153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melani-1994" NAME="Melani 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Melani AS; Gregorio A Di. Terapia di lunga durata con salmeterol per via inalatoria Vs teofillina orale a lento rilascio: effetti sulla saturazione ossiemoglobinica durante il test del cammino in pazienti con BPCO severo. Lotta contro la TBC e malattie polmonari soc. 1994;64: 331-336.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melani AS, Di Gregorio A</AU>
<TI>Long-term therapy with inhaled salmeterol versus oral slow release theophylline. Effects on oxygen saturation during the walking test in patients with severe COPD</TI>
<TO>Terapia di lunga durata con salmeterol per via inalatoria Vs teofillina orale a lento rilascio: effetti sulla saturazione ossiemoglobinica durante il test del cammino in pazienti con BPCO severo. Lotta contro la TBC e malattie polmonari soc</TO>
<SO>Lotta Contro La Tuberculosi e Le Malattie Polmonari Sociali</SO>
<YR>1994</YR>
<VL>64</VL>
<NO>4</NO>
<PG>331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melillo-1989" NAME="Melillo 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melillo G, Balzano G, Jodice F, De Felice A, Campisi V, Capone M, et al</AU>
<TI>Treatment of reversible chronic airways orbstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>6</NO>
<PG>397-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morandini-1989" NAME="Morandini 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morandini GC, Finiguerra M, Conti P, Bernocchi D, Manini G</AU>
<TI>Treatment of chronic bronchitis</TI>
<TO>Combined therapy with sustained-release theophylline (Teonova R) and a mucoactive drug sobrerol (Sobrepin R)</TO>
<SO>Clin Trials</SO>
<YR>1989</YR>
<VL>26</VL>
<NO>3</NO>
<PG>163-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oren--1997" NAME="Oren  1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oren R, Beeri M, Hubert A, Kramer M R, Matzner Y</AU>
<TI>Effect of theophylline on erythrocytosis in chronic obstructive pulmonary disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1997</YR>
<VL>157</VL>
<NO>13</NO>
<PG>1474-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poukkula-1989" NAME="Poukkula 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poukkula A, Korhonen UR, Huikuri H, Linnaluoto M</AU>
<TI>Theophylline and salbutamol in combination in patients with obstructive pulmonary disease and concurrent heart disease: effect on cardiac arrhythmias</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1989</YR>
<VL>226</VL>
<PG>229-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pulido-1989" NAME="Pulido 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pulido E, Pupita F, Battistoni C</AU>
<TI>Treatment of patients with chronic airways obstruction: a controlled study with bamyphylline</TI>
<SO>Pharmatherapeutica</SO>
<YR>1989</YR>
<VL>5</VL>
<PG>416-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacco-1995" NAME="Sacco 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Sacco C, Braghiroli A, Grossi E, Donner CF. The effects of doxofylline versus theophylline on sleep architecture in COPD patients. Monaldi Arch Chest Dis 1995;50: 98-103.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacco C, Braghiroli A, Grossi E, Donner CF</AU>
<TI>The effects of doxofylline versus theophylline on sleep architecture in COPD patients</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>1995</YR>
<VL>50</VL>
<PG>98-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shivaram-1997" NAME="Shivaram 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Shivaram U, Cash ME, Mateo F, Shim C. Effects of high-dose ipratropium bromide and oral aminophylline on spirometry and exercise tolerance in COPD. Respir Med 1997; 91: 327-334.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shivaram U, Cash ME, Mateo F, Shim C</AU>
<TI>Effects of high-dose ipratropium bromide and oral aminophylline on spirometry and exercise tolerance in COPD</TI>
<SO>Respiratory Medicine</SO>
<YR>1997</YR>
<VL>91</VL>
<PG>327-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siemon-1991" NAME="Siemon 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siemon G, Huber W, Maier-Stocker P</AU>
<TI>Euphylong in standard dosage: comparison with an international retard preparation for twice-daily administration in recommended dosage</TI>
<TO>In German</TO>
<SO>Pneumologie</SO>
<YR>1991</YR>
<VL>45</VL>
<PG>853-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID: 1812479"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steen-1980" NAME="Steen 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steen SN, Smith R, Thomas JS</AU>
<TI>Clinical efficacy of theophylline combination therapy for chronic obstructive airways disease</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>4</NO>
<PG>608-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-1981" NAME="Sutton 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutton PP, Pavia D, Bateman JR, Clarke SW</AU>
<TI>The effect of oral aminophylline on lung mucociliary clerance in man</TI>
<SO>Chest</SO>
<YR>1981</YR>
<VL>80</VL>
<NO>6</NO>
<PG>889-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svedmyr-1982" NAME="Svedmyr 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svedmyr K</AU>
<TI>Effects of oral theophylline combined with oral and inhaled beta-2 adrenostimulants in asthmatics</TI>
<SO>Allergy</SO>
<YR>1982</YR>
<VL>37</VL>
<NO>2</NO>
<PG>119-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taccola-1999" NAME="Taccola 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taccola M, Bancalari L, Ghignoni G, Paggiaro PL</AU>
<TI>Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>302-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanzj-1974" NAME="Tanzj 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanzj L, Andreini E, Romeo A</AU>
<TI>Use of orally administered hydro-alcohol solution of theophylline in chronic obstructive bronchopathy: preliminary study</TI>
<TO>L'impiego di una soluzione idroalcoolica di teofillina per os nella broncopatia cronica obstruttiva: studio preliminare</TO>
<SO>Cardiologia Pratica</SO>
<YR>1974</YR>
<VL>25</VL>
<NO>4</NO>
<PG>349-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tatsis-1988" NAME="Tatsis 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Tatsis G, Danos J, Gaga M, Pantelakis D, Veslemes M, Jordanoglou J. A single-blind crossover study of two different slow release theophylline preparations. J Intern Med Research 1988;16:452-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tatsis G, Danos J, Gaga M, Pantelakis D, Veslemes M, Jordanoglou J</AU>
<TI>A single-blind crossover study of two different slow release theophylline preparations</TI>
<SO>Journal of International Medical Research</SO>
<YR>1988</YR>
<VL>16</VL>
<NO>6</NO>
<PG>452-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1985" NAME="Taylor 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Taylor R, Buick B, Kinney C, Lowry RC, Mcdevitt DG. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985;131:747-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor D R, Buick B, Kinney C, Lowry RC, Mcdevitt DG</AU>
<TI>The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1985</YR>
<VL>131</VL>
<PG>747-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsukino-1998" NAME="Tsukino 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53: 269-273.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T</AU>
<TI>Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>1998</YR>
<VL>53</VL>
<PG>269-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Umut-1992" NAME="Umut 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Umut S, Gemicioglu B, Yildirim N, Barlas, Ozuner Z. Effect of theophylline in chronic obstructive lung disease. Intern J Clin Pharm Ther Toxic 1992, 30: 149-152.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Umut S, Gemicioglu B, Yildirim N, Barlas, Ozuner Z</AU>
<TI>Effect of theophylline in chronic obstructive lung disease</TI>
<SO>International Journal of Clinicial Pharmacology and Therapeutic Toxicology</SO>
<YR>1992</YR>
<VL>30</VL>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Andel-1999" NAME="Van Andel 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Andel AE, Reisner C, Menjoge SS, Witek TJ</AU>
<TI>Analysis of inhaled corticosteroids and oral theophylline uas among patients with stable COPD from 1987 to 1995</TI>
<SO>Chest</SO>
<YR>1999</YR>
<VL>115</VL>
<NO>3</NO>
<PG>703-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vereen-1986" NAME="Vereen 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vereen LE, Kinasewitz GT, George RB</AU>
<TI>Effect of aminophylline on exercise performance in patients with irreversible airway obstruction</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<NO>7</NO>
<PG>1349-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villani-1997" NAME="Villani 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Villani F, Maria P, Ronchi E, Galimberti M. Oral doxophylline in patients with chronic obstructive pulmonary disease. Inter J Clin Pharm Therap 1997;35:107-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villani F, Maria P, Ronchi E, Galimberti M</AU>
<TI>Oral doxophylline in patients with chronic obstructive pulmonary disease</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>1997</YR>
<VL>35</VL>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vyse-1989" NAME="Vyse 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vyse T, Cochrane GM</AU>
<TI>Controlled release salbutamol tablets versus sustained release theophylline tablets in the control of reversible obstructive airways disease</TI>
<SO>Journal of International Medical Research</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>1</NO>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiessmann-1975" NAME="Wiessmann 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Wiebmann KJ. Der einflub eines oralen aminophyllin-praparates mit retardwirkung auf die lungenfunktionsparameter bei obstruktiven atemwegserkrankungen. Deutsch Medizinische Wochenschrift 1975;36: 1781-1790.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiessmann KJ</AU>
<TI>Effect of a slow-release aminophylline on pulmonary function in obstructive respiratory disease</TI>
<TO>Der einfluss eines oralen Aminophyllin-Praparates mit Retardwirkung auf di Lungenfunktionsparameter bei obstruktiven Atemwegserkrankungen</TO>
<SO>Deutsch Medizinische Wochenschrift</SO>
<YR>1975</YR>
<VL>36</VL>
<NO>5</NO>
<PG>1781-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winter-1984" NAME="Winter 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winter RJ, Langford JA, George RJ, Deacock SJ, Rudd RM</AU>
<TI>The effects of theophylline and salbutamol on right and left ventricular function in chronic bronchitis and emphysema</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1984</YR>
<VL>78</VL>
<NO>4</NO>
<PG>358-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2001" NAME="Yang 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang J, Tu H-Y, Li Q-Q</AU>
<TI>Effect of theophylline on airway inflammation in asthma</TI>
<SO>Acta Pharmacol Sin</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>5</NO>
<PG>475-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ZuWallack-2001" NAME="ZuWallack 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ZuWallack R, Mahler D, Reilly D, Chruch N, emmett A, Rickard K, Knobil K</AU>
<TI>Salmeterol plus theophylline combination therapy in the treatment of COPD</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<PG>1661-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Appleton-2002" NAME="Appleton 2002" TYPE="COCHRANE_REVIEW">
<AU>Appleton S, Poole P, Smith B, Veale A, Bara A</AU>
<TI>Long acting beta2-agonists for COPD patients with poorly reversible airflow limitation</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATS-1995" NAME="ATS 1995" NOTES="&lt;p&gt;STANDARDS FOR THE DIAGNOSIS AND CARE OF PATIENTS WITH COPD. Am J Respir Crit Care 1995, 152:S77-120.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>American Thoracic Society</AU>
<TI>American Thoracic Society Standards for the diagnosis and care of patients with COPD</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152 Suppl</VL>
<PG>77-120</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atuk-1967" NAME="Atuk 1967" TYPE="JOURNAL_ARTICLE">
<AU>Atuk NO, Blaydes MC, Westervelt FB Jr, Wood JE Jr</AU>
<TI>Effect of aminophylline on urinary excretion of epinephrine and norepinephrine in man</TI>
<SO>Circulation</SO>
<YR>1967</YR>
<VL>35</VL>
<NO>4</NO>
<PG>745-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aubier-1983" NAME="Aubier 1983" TYPE="JOURNAL_ARTICLE">
<AU>Aubier M, Murciano D, Viires N, Lecocguic Y, Palacios S, Pariente R</AU>
<TI>Increased ventilation caused by improved diaphragmatic efficiency during aminophylline infusion</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1983</YR>
<VL>127</VL>
<NO>2</NO>
<PG>148-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aubier-1985" NAME="Aubier 1985" TYPE="JOURNAL_ARTICLE">
<AU>Aubier M, Roussos C</AU>
<TI>Effect of theophylline on respiratory muscle function</TI>
<SO>Chest 1985</SO>
<YR>1985</YR>
<VL>88 Suppl</VL>
<PG>91-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnette-2000" NAME="Barnette 2000" TYPE="JOURNAL_ARTICLE">
<AU>Barnette MS, Underwood DC</AU>
<TI>New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Belman-1996" NAME="Belman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Belman MJ, Botnick WC, Shin JW</AU>
<TI>Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>967-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergstrand-1980" NAME="Bergstrand 1980" TYPE="JOURNAL_ARTICLE">
<AU>Bergstrand H</AU>
<TI>Phosphodiesterase inhibition and theophylline</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1980</YR>
<VL>109 Suppl</VL>
<PG>37-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1997" NAME="BTS 1997" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Society</AU>
<TI>British Thoracic Society Guidelines for the Management of Chronic Obstructive Pulmonary Disease</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52 Suppl (5)</VL>
<PG>1-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Celli-2000" NAME="Celli 2000" TYPE="JOURNAL_ARTICLE">
<AU>Celli BR</AU>
<TI>The Importance of Spirometry in COPD and Asthma - Effect on Approach to Management</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<PG>15-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cleophas-1993" NAME="Cleophas 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cleophas TJ</AU>
<TI>Carry-over biases in clinical pharmacology</TI>
<SO>European Journal of Clinical Chemistry &amp; Clinical Biochemistry</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>12</NO>
<PG>803-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cleophas-1996" NAME="Cleophas 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cleophas TJ</AU>
<TI>Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>3</NO>
<PG>235-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Compton-2000" NAME="Compton 2000" NOTES="&lt;p&gt;abstract only&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Compton C, Duggan M, Cedar E, Nieman RB, Amit O, Tabona MV, et al</AU>
<TI>Ariflo® efficacy in a 12 month study of patients with asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<PG>A505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1987" NAME="Cooper 1987" TYPE="JOURNAL_ARTICLE">
<AU>Cooper CB, Davidson AC, Cameron IR</AU>
<TI>Aminophylline, respiratory muscle strength and exercise tolerance in chronic obstructive airway disease</TI>
<SO>Bulletin Europeen de Physiopathologie Respiratoire</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Darnall_x002d_Jr-1985" NAME="Darnall-Jr 1985" TYPE="JOURNAL_ARTICLE">
<AU>Darnall-Jr. RA</AU>
<TI>Aminophylline reduces hypoxic ventilatory depression: possible role of adenosine</TI>
<SO>Pediatric Research</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>7</NO>
<PG>706-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eaton-1980" NAME="Eaton 1980" TYPE="JOURNAL_ARTICLE">
<AU>Eaton ML, Green BA, Church TR, McGowan T, Niewoehner DE</AU>
<TI>Efficacy of theophylline in "irreversible" airflow obstruction</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1980</YR>
<VL>92</VL>
<NO>6</NO>
<PG>758-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ERS-1995" NAME="ERS 1995" NOTES="&lt;p&gt;ERS-Consensus Statement. Optimal assessement and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995, 8:1398-1420.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>European Respiratory Society Consensus Statement</AU>
<TI>Optimal assessement and management of chronic obstructive pulmonary disease (COPD)</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<PG>1398-420</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-1997" NAME="Evans 1997" TYPE="JOURNAL_ARTICLE">
<AU>Evans DJ, Taylor DA, Zetterstrom U, Chung KF, O'Connor BJ, Barnes PJ</AU>
<TI>A comparison of low dose inhaled budesonide plus theophylline and high dose inhaled budesonide for moderate asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>1412-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folgering-1994" NAME="Folgering 1994" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Folgering H, Herwaarden CV</AU>
<TI>Exercise limitations in patients with pulmonary diseases</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>1994</YR>
<VL>15</VL>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giembycz-2000" NAME="Giembycz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Giembycz MA</AU>
<TI>Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?</TI>
<SO>Drugs</SO>
<YR>2000</YR>
<VL>59</VL>
<NO>2</NO>
<PG>193-212</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gomez-2002" NAME="Gomez 2002" NOTES="&lt;p&gt;http://www.goldcopd.com&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gomez FP, Rodriguez-Roisin R</AU>
<TI>Global initiative for chronic obstructive lung disease (GOLD) guidelines for chronic obstructive pulmoary disease</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>2</NO>
<PG>81-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11845001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-1988" NAME="Guyatt 1988" NOTES="&lt;p&gt;GUYATT GH, TOWNSEND M, NOGRADI S, PUGSLEY SO, KELLER JL, NEWHOUSE MT. Acute response to bronchodilator: an imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern Med 1988, 148:1949-52.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT</AU>
<TI>Acute response to bronchodilator: an imperfect guide for bronchodilator therapy in chronic airflow limitation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1988</YR>
<VL>148</VL>
<PG>1949-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hatipoglu-1999" NAME="Hatipoglu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hatipoglu US, F Laghi F, Tobin MJ</AU>
<TI>Does inhaled albuterol improve diaphragmatic contractility in patients with Chronic Obstructive Pulmonary Disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>1916-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay-1992" NAME="Hay 1992" TYPE="JOURNAL_ARTICLE">
<AU>Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, et al</AU>
<TI>Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease</TI>
<SO>European Respiratory Journal</SO>
<YR>1992</YR>
<VL>5</VL>
<NO>6</NO>
<PG>659-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higbee-1982" NAME="Higbee 1982" TYPE="JOURNAL_ARTICLE">
<AU>Higbee MD, Kumar M, Galant SP</AU>
<TI>Stimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of action for theophylline effects</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1982</YR>
<VL>70</VL>
<NO>5</NO>
<PG>377-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horrobin-1977" NAME="Horrobin 1977" TYPE="JOURNAL_ARTICLE">
<AU>Horrobin DF, Manku MS, Franks DJ, Hamet P</AU>
<TI>Methyl xanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation</TI>
<SO>Prostaglandins</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" NOTES="&lt;p&gt;JADAD AR, MOORE A, CARROLL D, JENKINSON C, REYNOLDS JM, GAVAGHAN DJ, McQUAY HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996,  17:1-12.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Javaheri-1989" NAME="Javaheri 1989" TYPE="JOURNAL_ARTICLE">
<AU>Javaheri S, Evers JA, Teppema LJ</AU>
<TI>Increase in ventilation caused by aminophylline in the absence of changes in ventral medullary extracellular fluid pH and carbon dioxide tension</TI>
<SO>Thorax</SO>
<YR>1989</YR>
<VL>44</VL>
<NO>2</NO>
<PG>121-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Javaheri-1990" NAME="Javaheri 1990" TYPE="JOURNAL_ARTICLE">
<AU>Javaheri S, Guerra L</AU>
<TI>Lung function, hypoxic and hypercapnic ventilatory responses, and respiratory muscle strength in normal subjects taking oral theophylline</TI>
<SO>Thorax</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>10</NO>
<PG>743-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johannesson-1985" NAME="Johannesson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Johannesson N, Andersson K, Joelsson B, Persson C</AU>
<TI>Relaxation of lower esophageal sphincter and stimulation of gastric secretion and diuresis by antiasthmatic xanthines</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1985</YR>
<VL>131</VL>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerstjens-1999" NAME="Kerstjens 1999" TYPE="BOOK_SECTION">
<AU>Kerstjens HAM</AU>
<TI>Stable chronic obstructive pulmonary disease</TI>
<SO>Clinical evidence</SO>
<YR>1999</YR>
<EN>Issue 1</EN>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landsberg-1990" NAME="Landsberg 1990" TYPE="JOURNAL_ARTICLE">
<AU>Landsberg KF, Vaughan LM, Heffner JE</AU>
<TI>The effect of theophylline on respiratory muscle contractility and fatigue</TI>
<SO>Pharmacotherapy</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>4</NO>
<PG>271-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levine-1985" NAME="Levine 1985" TYPE="JOURNAL_ARTICLE">
<AU>Levine JH, Michael JR, Guarnieri T</AU>
<TI>Multifocal atrial tachycardia: a toxic effect of theophylline</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>i</VL>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marsh-1993" NAME="Marsh 1993" TYPE="JOURNAL_ARTICLE">
<AU>Marsh GD, McFadden RG, Nicholson RL, Leasa DJ, Thompson RT</AU>
<TI>Theophylline delays skeletal muscle fatigue during progressive exercise</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1993</YR>
<VL>147</VL>
<NO>4</NO>
<PG>876-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matthay-1986" NAME="Matthay 1986" TYPE="JOURNAL_ARTICLE">
<AU>Matthay RA, Mahler DA</AU>
<TI>Theophylline improves global cardiac function and reduces dyspnea in chronic obstructive lung disease</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1986</YR>
<VL>78</VL>
<NO>Pt 2</NO>
<PG>793-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendella-1982" NAME="Mendella 1982" TYPE="JOURNAL_ARTICLE">
<AU>Mendella LA, Manfreda J, Warren CP, Anthonisen NR</AU>
<TI>Steroid response in stable chronic obstructive pulmonary disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1982</YR>
<VL>96</VL>
<NO>1</NO>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitenko-1973" NAME="Mitenko 1973" TYPE="JOURNAL_ARTICLE">
<AU>Mitenko PA, Ogilvie RI</AU>
<TI>Rational intravenous doses of theophylline</TI>
<SO>New England Journal of Medicine</SO>
<YR>1973</YR>
<VL>289</VL>
<PG>600-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" NAME="Mulrow 1997" NOTES="&lt;p&gt;MULROW CD, OXMAN AD, EDITORS. Cochrane Collaboration Handbook (updated 1 march 1997). In: The Cochrane Collaboration; Issue 1. Oxford: Update Software; 1997. Updated quarterly.&lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Mulrow CD, Oxman AD</AU>
<TI>Cochrane Collaboration Handbook (updated 1 march 1997)</TI>
<SO>The Cochrane Library</SO>
<YR>1997</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murciano-1984" NAME="Murciano 1984" TYPE="JOURNAL_ARTICLE">
<AU>Murciano D, Aubier M, Lecocguic Y, Pariente R</AU>
<TI>Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>311</VL>
<NO>6</NO>
<PG>349-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Donnell-1999" NAME="O'Donnell 1999" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell DE, Lam M, Webb KA</AU>
<TI>Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>542-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okubo-1987" NAME="Okubo 1987" TYPE="JOURNAL_ARTICLE">
<AU>Okubo S, Konno K, Ishizaki T, Kubo M, Suganuma T, Takizawa T</AU>
<TI>Effect of theophylline on respiratory neuromuscular drive</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>33</VL>
<NO>1</NO>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauwels-2000" NAME="Pauwels 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pauwels RA</AU>
<TI>National and International Guidelines for COPD - The need for evidence</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117 Suppl</VL>
<PG>20-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Persson-1986" NAME="Persson 1986" NOTES="&lt;p&gt;PERSSON CGA. Overview of effects of theophylline. J Allergy Clin Immunol 1986, 78:780-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Persson CGA</AU>
<TI>Overview of effects of theophylline</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1986</YR>
<VL>78</VL>
<PG>780-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raguso-1996" NAME="Raguso 1996" NOTES="&lt;p&gt;RAGUSO CA, COGGAN AR, LABROS SS, GASTALDELLI A, WOLFE R. Effect of theophylline on substrate metabolism during exercise. Metabolism 1996,  45:1153-60.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Raguso CA, Coggan AR, Labros SS, Gastaldelli A, Wolfe R</AU>
<TI>Effect of theophylline on substrate metabolism during exercise</TI>
<SO>Metabolism</SO>
<YR>1996</YR>
<VL>45</VL>
<PG>1153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ritchie-1975" NAME="Ritchie 1975" TYPE="BOOK_SECTION">
<AU>Ritchie JM</AU>
<TI>Central nervous stimulants: the xanthines</TI>
<SO>The Pharmacological Basis of Therapeutics</SO>
<YR>1975</YR>
<PG>367-8</PG>
<ED>Goodman LS, Gilman A</ED>
<PB>Macmillan Publishing Co Inc</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherman-1996" NAME="Sherman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sherman MS, Lang DM, Matityahu A, Campbell D</AU>
<TI>Theophylline improves measurements of respiratory muscle efficiencyTheophylline improves measurements of respiratory muscle efficiencyTheophylline improves measurements of respiratory muscle efficiency</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>6</NO>
<PG>1437-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spinelli-1991" NAME="Spinelli 1991" TYPE="JOURNAL_ARTICLE">
<AU>Spinelli A, Fanelli A, Gorini M, Sanna A, Francois C, Scano G</AU>
<TI>Control of breathing in patients with chronic pulmonary obstructive disease: response to bamiphylline</TI>
<SO>Respiration</SO>
<YR>1991</YR>
<VL>58</VL>
<NO>5-6</NO>
<PG>241-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Varriale-1993" NAME="Varriale 1993" TYPE="JOURNAL_ARTICLE">
<AU>Varriale P, Ramaprasad S</AU>
<TI>Aminophylline induced atrial fibrillation</TI>
<SO>Pacing and Clinical Electrophysiology</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>1953-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verren-1986" NAME="Verren 1986" NOTES="&lt;p&gt;VERREN LE, KINASEWITZ GT, GEORGE RB. Effect of aminophylline on exercise performance in patients with irreversible airway obstruction. Arch Inter Med 1986, 146:1349-51.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Verren LE, Kinasewitz GT, George RB</AU>
<TI>Effect of aminophylline on exercise performance in patients with irreversible airway obstruction</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<PG>1349-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Webb-1990" NAME="Webb 1990" TYPE="JOURNAL_ARTICLE">
<AU>Webb K, Fox L, Muir C, O'Donnell DE</AU>
<TI>Ipratropium bromide reduces exertional dyspnea in patoents with severe chronic airflow limitation</TI>
<SO>Chest</SO>
<YR>1990</YR>
<VL>98</VL>
<PG>1135</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolkove-1989" NAME="Wolkove 1989" TYPE="JOURNAL_ARTICLE">
<AU>Wolkove N, Dajczman E, Colacone A, Kreisman H</AU>
<TI>The relationship between pulmonary function and dyspnea in obstructive lung disease</TI>
<SO>Chest</SO>
<YR>1989</YR>
<VL>96</VL>
<PG>1247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woodcock-1983" NAME="Woodcock 1983" NOTES="&lt;p&gt;WOODCOCK AA, JOHNSON MA, GEDDES DM. Theophylline prescribing, serum concentrations, and toxicity. Lancet 1983, 1:610-3.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Woodcock AA, Johnson MA, Geddes DM</AU>
<TI>Theophylline prescribing, serum concentrations, and toxicity</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<PG>610-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wrenn-1991" NAME="Wrenn 1991" TYPE="JOURNAL_ARTICLE">
<AU>Wrenn K, Slovis CM, Murphy F, Greenberg RS</AU>
<TI>Aminophylline therapy for acute bronchospastic disease in the emergency room</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<NO>4</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yung-1998" NAME="Yung 1998" TYPE="JOURNAL_ARTICLE">
<AU>Yung M, South M</AU>
<TI>Randomised controlled trial of aminophylline for severe acute asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>5</NO>
<PG>405-10</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Alexander-1980">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: double blind, identical looking placebo theophylline tablets were used.<BR/>4) Withdraws / drop-outs: 13 drop-outs. 5 placebo group and 4 theophylline group did not finish both study periods and are not included in the data analysis. 2 from each drug regimen dropped out as a result of acute respiratory distress that was attributed to pulmonary infection.<BR/>5) Duration of intervention: 4 weeks.<BR/>6) Design: crossover groups.<BR/>7) Jadad quality score: 3<BR/>8) Location: Iowa, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: Outpatients with moderate to severe COPD, stable, FEV1 less than 60 % of predicted, all had smoking histories of greater than 20 pack-years.<BR/>2) Definition of COPD: FEV1 at least less than 60% of predicted and a chronic, steadily declinig FEV1 and forced expiratory flow during the middle half of the forced vital capacity (FEF 25% to 75%).<BR/>3)Type of exercise test: None.<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 59.3. <BR/>6) FEV1: not described.<BR/>7) Number of patients: 53 men. Drop-out: 13. Final number of patients: 40. <BR/>8) Baseline therapy: Bronchodilators and corticosteroids were not allowed during the study, but other maintence medications were continued.<BR/>9) Exclusion criteria: Non-compliant patients (identified by pill counts and by observing serum theophylline concentration during the dose titration period, history of asthma, sputum and peripheral blood eosinophilia or another known cause for pulmonary insufficiency, fluctuation results in pulmonary function tests during a period of several years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 40, completed the study)<BR/>1) Drug: Theophylline. <BR/>2) Short or long action: Short-action<BR/>3) Dose: 100 mg four times daily<BR/>4) Washout period: not mentioned.<BR/>5) Theophylline blood level: during titration period to establish steady-state (10 to 20 ug/ml) theophylline serum levels (1.5 to 2.0 hours after the second dose of the day) and on the day of entry into the trial, and on the final day of each treatment period. Mean serum theophylline level during active therapy was 15.1 (SD 4.22) ug/ml. </P>
<P>PLACEBO GROUP ( n = 40, completed the study ).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (FVC (L), FVC (% pred), FEV1 (L), FEV1 (% Pred). <BR/>2) Resting arterial blood gases<BR/>3) Maximal voluntary ventilation. MVV (maximum voluntary ventilation (L), MVV (% pred).<BR/>4) Diary questionnaire, about pulmonary symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Anderson-1982">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, placebo was used and had the same appearance as theophylline tablets.<BR/>4) Withdraw / Drop-out: 4 withdraws, (one because of a confusional state attributed to alcohol withdrawal and 3 because of side effects - nightmares in one, headache in one and nausea and headache in one. (4/17 = 23%). <BR/>5) Duration of intervention: 3 periods of 8 days each, with one week washout.<BR/>6) Design: Cross-over groups.<BR/>7) Jadad quality Score: 3<BR/>8) Location: Newport, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: patients that fulfilled the Medical Research Council criteria for chronic bronchitis, all patients were ex-smokers.<BR/>2) Definition of COPD: The Medical Research Council criteria for chronic bronchitis (MRC, 1965).<BR/>3)Type of exercise test: none.<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 58, (range 34 to 70 years).<BR/>6) FEV1: Mean = 1.34, SD 0.122 (L).<BR/>7) Number of patients: 21 (17 men and 4 women). <BR/>8) Baseline therapy: corticosteroids were not allowed, but other maintence medications were permitted including inhaled bronchodilators.<BR/>9) Exclusion criteria: bronchial asthma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP ( n = 21, completed the study ).<BR/>1) Drug: Theophylline (Nuelin SA)<BR/>2) Short or long action: Long-action (Nuelin SA)<BR/>3) Dose: 350 mg daily theophylline for 4 days followed by 700 mg daily for four days with matching placebo for 8 days with one week washout period between crossover.<BR/>4) Washout period: 1 week.<BR/>5) Theophylline blood level: measured on the last day of each study period. The mean daily dose of theophylline for the whole group was 9.2 mg/Kg range 6-13.2 mg/Kg.</P>
<P>PLACEBO GROUP: n = 21 completed the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests PEFR, (FVC (L), FVC (% pred), FEV1 (L), FEV1 (% Pred). <BR/>2) Symptom scores<BR/>3) Side effects: 6 patients had nausea or headache in theophylline group. One patient had insomnia during the placebo week.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No.<BR/>2) Sample size and statistical power: not reported. <BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chrystyn-1988">
<CHAR_METHODS>
<P>1) Randomisation: patients were randomly allocated to the order of treatment by four identical Latin squares. <BR/>2) Allocation concealment: Not described. <BR/>3) Masking: The dose changes were effected in a single blind manner with matching placebo tablets.<BR/>4) Withdraw/Drop-out: 5 drop-out /38 (13,16%).<BR/>5) Duration of intervention: 2 months. 4 consecutive two month treatment periods (total = 8 months). Four periods: placebo, low, medium and high theophylline serum concentrations.<BR/>6) Design: Crossover groups.<BR/>7) Jadad uality score: 2<BR/>8) Location: West Yorkshire, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:COPD, moderate to severe obstruction of airflow. <BR/>2) Definition of COPD: Medical Research Council definition. <BR/>3)Type of exercise test: Six min waking test<BR/>4) Definition of stable COPD: not defined. But no patients were recruited who had an acute exacerbation in the previous 2 weeks.<BR/>5) Age: Mean = 61.2, SD 5.71 years (range 53 to 73)<BR/>6) FEV1: Mean = 29.1, SD 12.4 (% predc) <BR/>7) Initial total number of patients: 38. Drop-out: 5. Final patients number: 33 ( 30 men and 3 women). <BR/>8) Baseline therapy: Inhalation and oral corticosteroids and other bronchodilators were continued.<BR/>9) Exclusion criteria:Asthma or allergy, &gt; = 15% improvement in FEV1 20 min after inhaling 500 ug terbutaline sulphate, known sensitivity to methylxanthine, severe cardiac disease or other disease that might interfere with exercise testing.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE 3 GROUP- low dose ( n = 19), medium dose (n = 12), high dose (n = 10), completed the study. <BR/>1) Drug: Theophylline<BR/>2) Short or long action: Long-action<BR/>3) Dose: 3 doses used; low (5 to 10 mg/l), medium (10 to 15 mg/l) and high (15 to 20 mg/l). Used the medium dose only for the review as it is clinically the most relevant dose resulting in therapeutic plasma levels. <BR/>4) Washout period: not mentioned.<BR/>5) Theophylline blood level: measured at the end of each two month period.</P>
<P>PLACEBO GROUP ( n = 22 )</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (FEV1), (FVC), (SVC) (L), TLC measured by helium dilution (L), FRC measured by helium dilution (L), TLC measured by whole body plesthymography (L), FRC measured by whole body plesthymography (L) and trapped gas volume (L).<BR/>2) Exercise testing : six minute walking test<BR/>3) Visual analogue scale for dyspnoea (10 cm)<BR/>4) Peak expiratory flow (L/min.)<BR/>5) Side effects: nausea, insomnia, dyspepsia, headache, cramp, tremor (theophylline group)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dullinger-1986">
<CHAR_METHODS>
<P>1) Randomisation: not described (block design). <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, placebo tables were identical in appearance to theophylline tablets.<BR/>4) Withdraw/Drop-out: none.<BR/>5) Duration of intervention: 1 x 4 week as 4 different combinations of treatments were tested. <BR/>6) Design: Cross-over group<BR/>7) Jadad quality score: 3<BR/>8) Location: Minneapolis, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: COPD, outpatients.<BR/>2) Definition of COPD: FEV1 less than 1.5 L and FEV1/FVC of less than 60%.<BR/>3)Type of exercise test: 12 minute walk test<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 61 years ( range 53 to 72 years).<BR/>6) FEV1: Mean = 2.63 L (range 1.69 to 3.74)<BR/>7) Number of patients: 10 men. withdraw: 0<BR/>8) Baseline therapy: Not described.<BR/>9) Exclusion criteria: presence of significant chest abnormalities on x-ray, asthma, history of atopy, sputum or blood eosinophilia, absence of long-term smoking, frequent episodic attacks of wheeziness, regular use of corticosteroids, FEV1 response to an inhaled beta-agonist greater than 25% of baseline or co-existing disease which might interfere with exercise testing.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP VERSUS PLACEBO ( n = 10, completed the study)<BR/>1) Drug: Theophylline (Theo-Dur, Key Pharmaceuticals)<BR/>2) Short or long action: Long-action<BR/>3) Dose: twice daily in amounts to provide average plasma concentrations of 10 to 15 ug/ml.<BR/>4) Washout period: not mentioned.<BR/>5) Theophylline blood level: measured on the first day of the initial baseline study and at day 6 of each period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests: FVC (L), FEV1 (L). <BR/>2) Exercise testing (12 minute walking test and Incremental cycle ergometry test)<BR/>3) Dyspnea (oxygen cost diagram - OCD and breathlessness rating - BR) <BR/>4) Side effects: No reports of adverse effects from any of the treatments.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fink-1994">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, using identical placebo tablets to active treatment. <BR/>4) Withdraw/Drop-out: none.<BR/>5) Duration of intervention: 1 month.<BR/>6) Design: Cross-over groups<BR/>7) Jadad quality Score: 2<BR/>8) Location: Tel Aviv, Israel<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:COPD, severe, stable, smokers or former smokers.<BR/>2) Definition of COPD: FEV1 less than 50% of predicted.<BR/>3)Type of exercise test: Incremental cycle-ergometer. <BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 68.5, SD 3.3 years<BR/>6) FEV1: Mean = 38.3, SD 8.6 (% pred) and Mean = 1.06, SD 2.8 (L)<BR/>7) Number of patients: 22 ( 17 men and 5 women), withdraw: 0<BR/>8) Baseline therapy: Inhalation corticosteroids and other bronchodilators.<BR/>9) Exclusion criteria: known cardiac disease or cardiac disorders shown on the baseline incremental exercise test.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 22, completed the study)<BR/>1) Drug: Theophylline (Theotrim, Trima Lab., Israel)<BR/>2) Short or long action: Long-action<BR/>3) Dose: 300 mg theophylline (twice daily). Patients weighing less than 60 Kg took 200 mg twice per day. <BR/>4) Washout period: 2 weeks.<BR/>5) Theophylline blood level: measured on the day of the initial baseline study and after the first week of treatment. The dose was adjusted if the level was below 55.5umol/l. This adjustment was repeated until all patients had a blood level above 55.5umol/l.</P>
<P>PLACEBO GROUP ( n = 22, completed the study )</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests FVC (L), FVC (% pred), FEV1 (L), FEV1 (% pred). <BR/>2) Exercise testing (incremental exercise cycle ergometer test - WR, VO2max, HR, respiratory rate and ventilation, VO2max/HR (maximum oxygen pulse), VEmax/MVV (dyspnoea index), anaerobic threshold (VE/VO2slope).<BR/>3) Resting arterial blood gases<BR/>4) Maximal voluntary ventilation (MVV) (L), MVV (% pred).<BR/>5) Side effects: not described.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Guyatt-1987">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment not described.<BR/>3) Masking: Double blind, placebo tablets were identical in appearance to active treatment.<BR/>4) Withdraw/Drop-out: 8 drop-outs.<BR/>5) Duration of follow up: 4 treatment periods, each of 2 week duration, during which they received the follwing combination: placebo-placebo, placebo-salbutamol (inhaler), placebo-theophylline, and salbutamol (Inhaler)-theophylline. <BR/>6) Design: Crossover group<BR/>7) Jadad quality Score: 3<BR/>8) Location: Ontario, Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: COPD.<BR/>2) Definition of COPD: FEV1 less than 70% and FEV1/FVC of less than 0.7.<BR/>3) Type of exercise test: 6 minute walk test<BR/>4) Definition of stable COPD: change in respiratory medication in the month prior to entry or hospitalisation in the previous 2 months.<BR/>5) Age: Mean = 65.3 years, SD 7.4.<BR/>6) FEV1: Mean = 1.02 L, SD 0.38. 7) Number of patients: 27 men. Dropout: 8 (1 angina, 1 for surgery to remove a lipoma, 1 found the study too inconvenient, and 1 dropped out after a respiratory tract infection (during salbutamol period). Final number of patients: 19.<BR/>8) Baseline therapy: Patients were instructed not to use their own medication under any circumstances and to contact a physician, who was available full-time. If patients deteriorated, they were seen immediately, all outcome measures were obtained, and the patient was started on the next period's medication without the code being broken.<BR/>9) Exclusion criteria: a) inability to tolarate a theophylline level of greater than 12 ug/ml, b) a documented improvement in FEV1 of 25% or more in response to a trial of orally administered steroids, c) a documented improvement in FEV1 of 25% or more after inhaling 200 umg of salbutamol, d) asthma, e) clinical instability, f) use of orally administered or inhaled anticholonergic preparations.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 19, completed the study)<BR/>1) Drug: Theophylline<BR/>2) Short or long action: Short-action<BR/>3) Dose: Patients were given a previously titrated dose of theophylline to achieve a level of at least 65, and, if possible, close to 100 mmol/L. <BR/>4) Washout period: There was no washout period, but data from the first 3 days of each period was excluded.<BR/>5) Theophylline blood level: measured before the start of the study. In each treatment periods (the mean theophylline level during periods of active drug was 12.3 +- 2.9 ug/ml.</P>
<P>PLACEBO GROUP (n = 19, completed the study)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (FEV1 and FVC and Peak flow)<BR/>2) Exercise testing (6 minute walking test)<BR/>3) Dyspnoea (visual analogue scale)<BR/>4) Quality of life questionaire <BR/>4) Side effects: 3 shortness of breath, 1 gastrointestinal upset (periods had to be terminated before).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: Yes. Patients were recruited of more than 1,000 patients with CAL including all such patients seen in 10 secondary care respirology practices in a metropolitan area of approximately 500,000 people in the previous 2 years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Iversen-1992">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: double blind, identical looking placebo theophylline tablets were used.<BR/>4) Withdraws / drop-outs: not mentioned.<BR/>5) Duration of intervention:4 weeks.<BR/>6) Design: crossover groups.<BR/>7) Jadad quality score: 2<BR/>8) Location: Hillerod, Denmark</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: severe COPD. <BR/>2) Definition of COPD: FEV1 was mean 0.99 SD 0.45 L, FVC mean 2.2 SD 0.68 L. <BR/>3)Type of exercise test: None. <BR/>4) Definition of stable COPD: not described.<BR/>5) Age: not reported as abstract only published. <BR/>6) FEV1: not described.<BR/>7) Number of patients:48 patients. Drop-out: not reported. 8) Baseline therapy: not reported in abstract. <BR/>9) Exclusion criteria: not reported in abstract.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 48)<BR/>1) Drug: Theophylline. <BR/>2) Short or long action: Long action, sustained release Theo-Dur<BR/>3) Dose: 300 mg twice daily<BR/>4) Washout period: not mentioned.<BR/>5) Theophylline blood level: mena 7.1 SD 3.6 mg/l. </P>
<P>PLACEBO GROUP ( n = 48)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests. <BR/>2) Arterial blood gases<BR/>3) Dyspnoea scores <BR/>4) Patients 'sense of well-being'<BR/>5) Daily beta-agonists usage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>As this study was reported as an abstract it was devoid of many details.<BR/>1) Intention-to-treat analyses: No<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kongragunta-1988">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, identical placebo used. <BR/>4) Withdraw/Drop-out: 0 withdraw and 2 drop-outs (1 in cycle exercise runs and 1 in duration of resistive breathing). <BR/>5) Duration of intervention: 3 days of treatment with theophylline (or placebo) to reach therapeutic plasma level than study measurements done. <BR/>6) Design: Cross-over<BR/>7) Jadad quality Score: 3<BR/>8) Location: Chicago, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:moderately severe COPD (mean FEV1 1.08), none hypercapnic.<BR/>2) Definition of COPD: not described.<BR/>3)Type of exercise test: Incremental cycle-ergometer exercise testing. <BR/>4) Definition of stable COPD: not described.<BR/>5) Age: not reported.<BR/>6) FEV1: Mean = 1.10 (L), SD (0.30) and Mean = 36.1 (% pred), SD (12.9)<BR/>7) Number of patients: 8. withdraw: 0<BR/>8) Baseline therapy: All medications were given in their regular dose, no patients were on corticosteroids at the time of the study. <BR/>9) Exclusion criteria: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP ( n = 8, completed the study )<BR/>1) Drug: Theophylline. <BR/>2) Short or long action: Long-action<BR/>3) Dose: not reported but therapeutic levels reach after third dose, mean 12.8 SD 4.4 ug/ml. <BR/>4) Washout period: 3 days. <BR/>5) Theophylline blood level: mean 12.8 SD 4.4 ug/ml. </P>
<P>PLACEBO GROUP ( n=8, completed the study )</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Maximal transdiaphragmatic pressures(Pdimax)<BR/>2) Exercise testing (Endurance)<BR/>3) Electromyograms of the quadriceps femoris<BR/>4) Inspiratory resistive breathing<BR/>5) Duration of resistive breathing runs<BR/>6) Changes in respiratory rate and duty cycle<BR/>7) Side effects: not described.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: yes.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Machraoui-1994">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: double blind, placebo tablets were used.<BR/>4) Withdraws / drop-outs: not mentioned.<BR/>5) Duration of intervention:4 days.<BR/>6) Design: crossover groups.<BR/>7) Jadad quality score: 3<BR/>8) Location: Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: COPD<BR/>2) Definition of COPD: <BR/>3)Type of exercise test: None.<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: <BR/>6) FEV1:<BR/>7) Number of patients: 25 (18M). Drop-out: not reported. Final number of patients: not reported. <BR/>8) Baseline therapy: all concomitant therapy continued for the duration of the study. <BR/>9) Exclusion criteria: Left ventricular disease excluded with history, clinical diagnosis and chest x-ray. No electrolyte imbalances, dysproteinaemia or liver and kidney dysfunction or acidosis allowed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 25)<BR/>1) Drug: Theophylline. <BR/>2) Short or long action: Short-action<BR/>3) Dose: 400 mg bd for 4 days.<BR/>4) Washout period: 3 days<BR/>5) Theophylline blood level: done on the 4th and 11 days of the study. </P>
<P>PLACEBO GROUP ( n = 25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Arterial blood gases<BR/>2) ECG<BR/>3) Heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mahler-1985">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, with placebo identical in appearance to theophylline tablets.<BR/>4) Withdraw/Drop-out: none.<BR/>5) Duration of intervention: 2 x 4 weeks <BR/>6) Design: Cross-over groups<BR/>7) Jadad quality score: 3<BR/>8) Location: West Haven, Connecticut, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:COPD, stable, outpatients, at least moderate air-flow obstruction, less than 65 % of predicted, ability to exercise on an upright bicycle ergometer, and willingness to discontinue all medications for the period of the study.<BR/>2) Definition of COPD: FEV1 at least less than 65% of predict, with nonreversible airway obstruction, defined as less than 15% improvement in FEV1 after an inhaled bronchodilator.<BR/>3)Type of exercise test: 12 min walking test and submaximal steady state as well as progressive, incremental exercise on the bicycle ergometer.<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 60, SD 7 years<BR/>6) FEV1: Mean = 40 (% pred) and Mean= 1.36, SD 0.67 (L)<BR/>7) Number of patients: 12 men. withdraw: 0<BR/>8) Baseline therapy: Patients were instructed to use only an inhaled bronchodilator for respiratory symptoms.<BR/>9) Exclusion criteria: History of asthma or electrocardiographic evidence of coronary artery disease, valvular heart disease, hypertension, or primary myocardial disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 12, completed the study)<BR/>1) Drug: Theophylline (Theo-Dur, Key Pharmaceutical, Inc., Miami, FL)<BR/>2) Short or long action: Long-action<BR/>3) Dose: Initial 13 mg/Kg/day in 2 divided doses based on lean body weight.<BR/>4) Washout: 2 weeks<BR/>5) Theophylline blood level: measured on the fourth day of the study, theophylline blood level measured using HPLC in patients receiving theophylline as well as placebo. If the level was less than 10 um/ml, then the dosage was increased by 200 to 400 mg/day; in those receiving placebo, the dosage was randomly changed on the fourth day in some patients. In all patients who had a change in initial dosage of medication, theophylline level was remeasured on the seventh day. All patients receiving theophylline had a therapeutic blood level (10 to 20 ug/ml).</P>
<P>PLACEBO GROUP ( n = 12, completed the study ).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (FVC (L), TLC (by body plethysmography), DLCO (ml/min/mmHg), FEV1 (L), FEV1 (% Pred). <BR/>2) Exercise testing: 12 min walking test (incremental and endurance exercise cycle ergometer test - WR, VO2max, HR, respiratory rate and ventilation, VO2max/HR, VEmax/MVV, anaerobic threshold (VE/VO2slope).<BR/>3) Resting arterial blood gases<BR/>4) Dyspnea index<BR/>5) Side effects: none occured. All patients tolerated the theophylline and placebo medications without adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: yes. 20 patients with COPD were selected from outpatient clinics. After specific tests 12 patients were selected for the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marvin-1983">
<CHAR_METHODS>
<P>1) Randomisation: not described<BR/>2) Allocation concealment: coded in the pharmacy.<BR/>3) Masking: Double blind, placebo controlled. The code was not broken under any circumstances until completion of the entire study.<BR/>4) Withdraw/Drop-out: none.<BR/>5) Duration of intervention: 10 days (four arms tothe study therefore 10 days x 4). <BR/>6) Design: Cross-over<BR/>7) Jadad quality score: 3<BR/>8) Location: Little Rock, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:COPD severe outpatients, clinically stable, smoking history of greater than 20 pack-years.<BR/>2) Definition of COPD: FEV1 less than 50% of predicted.<BR/>3) Type of exercise test: Incremental cycleergometer and steady-state exercise testing<BR/>4) Definition of stable COPD: not refered.<BR/>5) Age: Mean = (?) range 50 to 69 years<BR/>6) FEV1: Mean = 1.03, SD 0.34 (L)<BR/>7) Number of patients: 15 men. withdraw: 0<BR/>8) Baseline therapy: All medications with cardiopulmonary effect were discontinued for 72 hours.<BR/>9) Exclusion criteria: Asthma, presence of greater than 5% eosinophils on peripheral blood smear, primary cardiovascular disease (angina, systemic hypertension, ventricular arrhythmia), evidence of left ventricular decompensation, other complicating systemic illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 15, completed the study)<BR/>1) Drug: Theophylline (Elixophylline)<BR/>2) Short or long action: Short-action<BR/>3) Dose: 200 mg theophylline (four times daily) for 10 days. <BR/>4) Washout: not reported. <BR/>5) Theophylline blood level: measured before and after 10 days of theophylline treatment. The dose was not adjusted.</P>
<P>PLACEBO GROUP ( n = 15, completed the study )</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Compliance with medication<BR/>2) Exercise testing (steady-state exercise (60% of the maximal work load during 6 minutes)<BR/>3) Shortness of breath: using a simple graded scale (absent = 0, mild = 1, moderate = 2, severe = 3). <BR/>4) Wheezing: same simple scale as shortness of breath (above).<BR/>5) Side effects: 'intolerance' in theophylline group (only one patient)<BR/>6) Lung function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mulloy-1993">
<CHAR_METHODS>
<P>1) Randomisation: not specified. <BR/>2) Allocation concealment: The treatment packs containing medications were sealed in advance.<BR/>3) Masking: Double blind, placebo controlled.<BR/>4) Withdraw/Drop-out: 2/12 (17%).<BR/>5) Duration of intervention: 3 weeks x 2 (first week dose adjustments followed by 2 weeks of treatment).<BR/>6) Design: Crossover group.<BR/>7) Jadad quality score: 3<BR/>8) Location: Dublin, Ireland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:COPD, clinically stable.<BR/>2) Definition of COPD: FEV1 less than 50% of predicted, with less than 15% improvement in FEV1 2O min. after 400 ug of salbutamol via inhaler.<BR/>3)Type of exercise test: Incremental treadmill exercise testing<BR/>4) Definition of stable COPD: Yes, (none had exacerbation of the COPD for at least 6 wk before entry into the study.<BR/>5) Age: (range 51 to 84). Mean = 4.2, SD 5.39<BR/>6) FEV1: 0.74 to 1.39 (range 20 to 47%). Mean = 0.91, SD 0.21<BR/>7) Number of patients: 12 ( 9 men and 1 woman). 2 drop-out. Final number of patients: 10.<BR/>8) Baseline therapy: Predinisone, duovent inhaler, beclomethasone inhaler, ipratropium inhaler, salbutamol inhaler, theophylline.<BR/>9) Exclusion criteria: history of cardiac (other than cor pulmonale) or hepatic disease. Taking hypnotics, sedatives, or any medication known to interfere with the metabolism or absorption of theophylline, smokers, asthma, blood eosinophilia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n=10, completed the study)<BR/>1) Drug: Theophylline (Napp Lab, Cambridge)<BR/>2) Short or long action: Long-action<BR/>3) Dose: 400 mg theophylline bd (10:00 AM and 10 PM). Patients weighing less than 70 kg took 300 mg bd.<BR/>4) Washout: 1 week, when dose adjustments were made for both the active and placebo arms. <BR/>5) Theophylline blood level: measured during the first week in baseline period and during the subsequent week in both active and placebo groups. The dose was adjusted in a blinded fashion in those on active treatment. Adjustments were made until all patients had a blood level between 10 and 20 mg/l.</P>
<P>PLACEBO GROUP (n = 10, completed the study).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests<BR/>2) Incremental exercise testing<BR/>3) Resting arterial blood gases and oxygen saturation.<BR/>4) Sleep alterations<BR/>5) Side effects: Nausea, only one patient (this patient had not taken theophylline before as the other 9 had).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: Yes. Randomised outpatients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Murciano-1989">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, placebo identical to theophylline in appearance.<BR/>4) Withdraw/Drop-out: none.<BR/>5) Duration of follow up: 2 months. (two months of placebo and two months of treatment + 8-day washout period between periods).<BR/>6) Design: Cross-over group design.<BR/>7) Jadad quality score: 3<BR/>8) Location: Clichy, France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:COPD, clinically stable. Smokers (15/ 60 - 25%), former smokers (43/ 60 - 72%) and nonsmokers (2/60 - 3%).<BR/>2) Definition of COPD: a change in FEV1 of less 15% after the administration of 400ug albuterol.<BR/>3)Type of exercise test: none.<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 61, SD 8 years<BR/>6) FEV1: Mean = 31.6, SD 12.5 (% pred) <BR/>7) Number of patients: 60. <BR/>8) Baseline therapy: No inhalation corticosteroids or other bronchodilators. Antibiotics only when infection was evidenced by an increased production of purulent sputum. Oxygen therapy (13 patients) was maintained at an identical flow and duration throughout the study.<BR/>9) Exclusion criteria: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 60, completed the study)<BR/>1) Drug: Theophylline (Theostat, Theoplus, Sinbio Laboratories, Paris).<BR/>2) Short or long action: Long-action<BR/>3) Dose: 10 mg per Kg of body weight per day of theophylline (twice daily). <BR/>4) Washout: 8 days.<BR/>5) Theophylline blood level: measured after one week in each treatment period with use of HPLC, and the results were reviewed by an independent observer. If necessary, the dose of theophylline was adjusted to obtain a plasma level of 10-20 mg/l.</P>
<P>PLACEBO GROUP (n = 60, completed the study)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (% of predicted), FEV1(% of predicted), FRC (% of predicted), Tidal volume (L). <BR/>2) Minute ventilation (L/min)<BR/>3) Airway resistence (cm of H2O/L/sec), <BR/>2) Resting arterial blood gases<BR/>3) Respiratory-Muscle Performance ( Ppl, Ppl max, Ppl/Ppl max)<BR/>4) Dyspnea (visual - analogue scale)<BR/>5) Side effects: not reported.<BR/>6) Respiratory Rate (breaths/min).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Newman-1994">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, placebo controlled. <BR/>4) Withdraw/Drop-out: none.<BR/>5) Duration of intervention: 2 x 4 weeks.<BR/>6) Design: Cross-over groups<BR/>7) Jadad quality score: 2<BR/>8) Location: Jerusalem, Israel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: COPD moderate to severe.<BR/>2) Definition of COPD: FEV1 25-60% of predict, PaO2 &gt;= 55mmHg and PCO2 &lt; = 50mmHg.<BR/>3) Type of exercise test: Incremental cycle-ergometer exercise testing<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 62.4, SD 5.6 years<BR/>6) FEV1: Mean = 43.4, SD 10.7 (% pred) and Mean = 1.15, SD 0.3 (L)<BR/>7) Number of patients: 12 (11 men and 1 women). withdraw: 0. 15 met the inclusion criteria but only 12 wanted to participate in the study.<BR/>8) Baseline therapy: Inhaled bronchodilators were allowed only to relieve symptoms, and the doses consumed was recorded.<BR/>9) Exclusion criteria: Asthma, blood eosinophils of &gt; 500 cell/mm3, more severe COPD or symptomatic coronary artery or cerebrovascular disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 12, completed the study)<BR/>1) Drug: Theophylline (Theotrim, Trima Lab., Israel)<BR/>2) Short or long action: Long-action<BR/>3) Dose: was titrated to achieve blood levels of 10 to 20 mg/l.<BR/>4) Washout: not reported.<BR/>5) Theophylline blood level: measured 2 to 3 h after the morning dose of 10 to 20 mg/L at 2 to 3 h after morning dose.</P>
<P>PLACEBO GROUP (n = 12, completed the study)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (FEV1 (L), FVC (L), flow volume loop). <BR/>2) Peak flow (L/min.)<BR/>3) Exercise testing: Incremental cycle ergometer test (VO2max (ml/min.), AT=anaerobic threshold (ml VO2/min., HR max (beats/min), VO2/HR max (ml/beat), VE max (L/min), exercise BR (L/min), R max)<BR/>4) Resting arterial blood gases<BR/>5) Maximal voluntary ventilation<BR/>6) PC20 (provocative concentration of inhalent needed to induce 20% fall in FEV1) <BR/>7) Neuropsychological evaluation tests (memory, attention, concentration)<BR/>8) Side effects: nausea, headache, loss of recent memory.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: Yes.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nishimura-1993">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind, placebo used which was identical to active treatment. <BR/>4) Withdraw/Drop-out: none.<BR/>5) Duration of intervention: 2 x 4 weeks.<BR/>6) Design: Cross-over groups<BR/>7) Jadad quality score: 3<BR/>8) Location: Kyoto, Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: COPD moderate to severe.<BR/>2) Definition of COPD: FEV1 &lt; 60% predicted, FEV1/FVC &lt; 0.7, aged between 50 to 75 yrs.<BR/>3)Type of exercise test: none<BR/>4) Definition of stable COPD: no exacerbation in the preceeding 3 months, no treatment with inhaled or systematic steroids in the preceeding 2 weeks.<BR/>5) Age: Mean = 64.3, SD 5.9 yrs<BR/>6) FEV1: Mean = 0.92, SD 0.38 (L) and Mean % predicted = 35.3, SD 14.0. <BR/>7) Number of patients: 12 (11 men and 1 women). withdraw: 1.<BR/>8) Baseline therapy: both Inhaled salbutamol (400ug) and ipratropium bromide (40ug) were allowed qid. <BR/>9) Exclusion criteria: asthma, heart disease or any other illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 12, completed the study)<BR/>1) Drug: Theophylline (Slow-bid, RPR, Japan)<BR/>2) Short or long action: Long-action<BR/>3) Dose: 400mg for 2 weeks, followed by 600mg for another 2 weeks.<BR/>4) Washout: not reported.<BR/>5) Theophylline blood level: ??</P>
<P>PLACEBO GROUP (n=12, completed the study)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (FEV1 (L), FVC (L). <BR/>2) Peak flow (L/min.)<BR/>3) Daily symptoms of cough, sputum, wheeze, and dyspnoea based on a smple scale of 1 to 4 (1 best, 4 worst) <BR/>4) Side effects: nausea, gastrointestinal effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nishimura-1995">
<CHAR_METHODS>
<P>1) Randomistion: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Double blind with matching placebo.<BR/>4) Withdraw/Drop-out: 7 drop-outs. One patient because he complained of urinary tract infection. Four patients because of exacerbation due to respiratory tract infection: Two during the theophylline period and two during the placebo period. Two in theophylline group because of gastrointestinal side effects. One patient in the theophylline group did not have theophylline level detected, he was excluded from the data analysis. Withdraw: 1.<BR/>5) Duration intervention: 4 weeks.<BR/>6) Design: cross-over groups<BR/>7) Jadad quality score: 2<BR/>8) Location: Kyoto, Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria:COPD, stable, age older 55 years, history of cigarette smoking of more than 20 pack-years, chest radiograph showing hyperinflation with or without a vascular deficiency pattern suggestive of pulmonary emphysema, smokers, former smokers, a best postbronchodilator ratio of the FEV1 to FVC of less than 70%.<BR/>2) Definition of COPD: FEV1 of less than 80% of the predicted value, according to the American Thoracic Society.<BR/>3)Type of exercise test: none.<BR/>4) Definition of stable COPD: no acute exacerbation of airflow obstruction within the preceding 3 months.<BR/>5) Age: Mean = 63.3, SD 4.7 years, range 55 to 73.<BR/>6) FEV1: Mean = 36.8, SD 17 (% pred) and Mean = 0.96, SD 0.43 (L)<BR/>7) Number of patients: 32 men. Drop-out: 7. Withdraw: 1. Final number of patients: 24. <BR/>8) Baseline therapy: salbutamol 400 ug and ipratropium bromide 80 ug qid.<BR/>9) Exclusion criteria: any history suggestive of asthma, heart disease, or any other illness. Patients treated with inhaled or systemic steroids in the preceding 3 weeks were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 24, completed the study)<BR/>1) Drug: Theophylline<BR/>2) Short or long action: Long-action<BR/>3) Dose: the daily doses of theophylline were predetermined to provide average serum concentration of more than 10 ug/ml.<BR/>4) Washout: not reported.<BR/>5) Theophylline blood level: was measured by fluorescence polarization immunoassay. The moment of the measured during the study and adjusted dose criteria was not described.</P>
<P>PLACEBO GROUP (n = 24, completed the study )</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests by body plethysmography (FVC (L), FVC (% pred), FEV1 (L), FEV1 (% Pred), <BR/>2) Peak expiratory flow rate.<BR/>3) Symptoms of cough, sputum, wheezing and shortness of breath, rated on a simple scale of one to four.<BR/>4) Side effects: 2 patents had gastrointestinal side effects in the theophylline group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Power-1992">
<CHAR_METHODS>
<P>ABSTRACT ONLY<BR/>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>3) Masking: Single blind, placebo controlled. <BR/>4) Withdraw/Drop-out: not reported.<BR/>5) Duration of intervention: 2 x 4 weeks.<BR/>6) Design: Cross-over groups<BR/>7) Jadad quality score: 1<BR/>8) Location: Dublin, Ireland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: COPD patients who did not demonstrate a bronchodilator response 'irreversible'.<BR/>2) Definition of COPD: not reported.<BR/>3) Type of exercise test: none<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: Mean = 67.4, SD 6.6 years<BR/>6) FEV1: Mean = 1.06, SD 0.53 (L), FVC 2.44, SD 0.88 (L).<BR/>7) Number of patients: 37<BR/>8) Baseline therapy: not reported.<BR/>9) Exclusion criteria: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 37)<BR/>1) Drug: Theophylline<BR/>2) Short or long action: Long-action<BR/>3) Dose: not reported but dosing was bd.<BR/>4) Washout: not reported.<BR/>5) Theophylline blood level: not reported. </P>
<P>PLACEBO GROUP (n = 37)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Spirometry <BR/>2) Peak flow (L/min.)<BR/>3) Symptom scores<BR/>4) 6 MW distance<BR/>5) Quality of life: CRDQ &amp; Nottingham Health Profile Index).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: not reported.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rivington-1988">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: randomly generated sequence.<BR/>3) Masking: Double blind, placebo controlled, 3 way crossover.<BR/>4) Withdraw/Drop-out: None but seven of the 12 who completed the active phase of the study were removed from the placebo phase because of increasing symptom severity.<BR/>5) Duration of intervention: 2 weeks x 3. Three arms in study but we will only use one active arm and the placebo arm as to avoid double counting the placebo group. <BR/>6) Design: Crossover groups<BR/>7) Jadad quality score: 3<BR/>8) Location: Ontario, Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: Stable COPD, not have asthma, aged 50 yrs and over and require chronic bronchodilator therapy.<BR/>2) Definition of COPD: FEV1:FVC ratio of &lt; 60% predicted and documented chronic airflow limitation.<BR/>3) Definition of stable COPD: not stated. <BR/>4) Type of exercise test: none<BR/>5) FEV1 % predicted Mean 37.4 SE 4.0, PaO2 Mean 73.3 SE 2.2 mmHg, PaCO2 Mean 40.9 SE 1.0 mmHg, Age Mean 64.7 SE 2.1. <BR/>6) Number of patients: 12 (8 men and 4 women). Withdraw: 1 due to exacerbation in active active phase. Initial number of patients: 13 patients.<BR/>7) Baseline therapy: During the trial patients were encouraged not to use bronchodilators other than their usual salbutamol inhaler and their usual inhaled or oral steroids. <BR/>8) Exclusion criteria: patients with clinically significant cardiac, renal, hepatic or metabolic disease, patients known to have taken drugs known to interfer with theophylline metabolism, and patients needing supplemental oxygen or were experiencing chronic respiratory failure = PaCO2 &gt; 55mmHg).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 12, completed the study)<BR/>1) Drug: Uniphyl or Theo-Dur (we usedthe results from the Uniphyl vs placebo comparison)<BR/>2) Short or long action: Long-action.<BR/>3) Dose: once daily.<BR/>4) Washout: one day. <BR/>5) Theophylline blood level: measured to give a morning trough of at least 7 ug/ml. </P>
<P>PLACEBO GROUP (n = 12)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Peak flow rate<BR/>2) Heart rate (mean and max).<BR/>3) ECG<BR/>4) Side effects: headache, nausea, vomiting recorded on a 0 to 6 scale.<BR/>5) Symptoms: cough, dyspnoea, wheeze, chest tightness recorded on a 0 to 6 scale.<BR/>6) Use of daily inhaled beta-agonists.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schmidt-1979">
<CHAR_METHODS>
<P>1) Randomisation: not reported. <BR/>2) Allocation concealment: the numbers 1 to 12 were randomly assigned to packages of six bottles containing 180 capsules of 200 mg of either theophylline or placebo. Six of these packages contained three bottles labeled months 4,5, and 6. Six packages contained drug and placebo in reverse manner.<BR/>3) Masking: Double blind. Placebo tablets had the same appearance as theophylline.<BR/>4) Withdraw/Drop-out: one dropped out after month 4 treatment. 3 patients had to be crossed over because of the treament efficacy, one after several days, one after 2 weeks, and the third after months.<BR/>5) Duration intervention: 3 months x 2 6) Design: Cross-over groups.<BR/>7) Jadad quality score: 5<BR/>8) Location: Pennsylvania, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion outpatients criteria:COPD, without improve 15% response to inhaled isoproterenol.<BR/>2) Definition of COPD: FEV1 less than 70% of predicted.<BR/>3)Type of exercise test: none.<BR/>4) Definition of stable COPD: not described.<BR/>5) Age: not described (range 30 to 70)<BR/>6) FEV1: Mean = 1.05, SD not described.<BR/>7) Number of patients:12. Drop-out: 1 (11 patients completed the study).<BR/>8) Baseline therapy: not reported.<BR/>9) Exclusion criteria: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 11, completed the study)<BR/>1) Drug: Elixophyllin 200mg capsules.<BR/>2) Short or long action: Short-action<BR/>3) Dose: 800 mg theophylline per day total (dosing was 200mg qid).<BR/>4) Washout: not reported<BR/>5) Theophylline blood level: not measured. </P>
<P>PLACEBO GROUP (n = 11, completed the study)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests (FVC (L), FVC (% pred), FEV1 (L), FEV1 (% pred), MMFER (L/min). Maximal mid flow expiratory rate. <BR/>2) Patient questionnaire pulmonary status<BR/>3) Symptom: subjective<BR/>4) Heart rate <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: no.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thomas-1992">
<CHAR_METHODS>
<P>1) Randomisation: not described. <BR/>2) Allocation concealment: not described.<BR/>2) Masking: Double blind. Placebo was indistinguishable from the active medication.<BR/>3) Withdraw/Drop-out: Two drop-out (one during the theophylline titration period for reasons unrelated to the study and the other during the second treatment phase due to severe dyspnoea - at which time he was receiving theophylline.<BR/>4) Duration of intervention: 2 weeks x 4. Four arms in study but we need only use 2 (3 versus 4). <BR/>6) Design: Crossover groups<BR/>7) Jadad quality score: 4<BR/>8) Location: Toronto, Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1) Inclusion criteria: Stable COPD, outpatients.<BR/>2) Definition of COPD: FEV1 less than 60 % of predicted normal and FEV1/FVC ratio less than 0.7.<BR/>3) Definition of stable COPD: not requiring additional therapeutic intervention.<BR/>5) Age: Mean= 63.1 years ( SD 4.6 years).<BR/>6) FEV1: Mean= 1.09 L (SD 0.35 and range 0.6 to 1.6 L)<BR/>7) Number of patients: 12 (6 men and 6 women). Withdraw: 2 .Initial number of patients: 14 patients.<BR/>8) Baseline therapy: No bronchodilators, other than the test medications or steroids were allowed during the trial. Medications patients were taking at time of study entry were continued at stable dosages throughout the trial.<BR/>9) Exclusion criteria: FEV1 or FVC values differed by more than 20 % in any spirometric tests performed during the preceding two years. Evidence of severe cardiac, hepatic, or renal disease; and if taking allopurinol, beta-blockers, oral corticosteroids, phenytoin, or cimetidine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>THEOPHYLLINE GROUP (n = 12, completed the study)<BR/>1) Drug: Phyllocontin, Purdue Frederick.<BR/>2) Short or long action: Long-action theophylline.<BR/>3) Dose: twice daily, at a previously determined dosage.<BR/>4) Washout: not reported. <BR/>5) Theophylline blood level: measured on the open-label theophylline dose-titration period during which their dosage of oral was adjusted to produce serum theophylline concentration of at least 10 mg/L, and as close as possible to 16.5 mg/L - between 4 and 6 h after dose.</P>
<P>PLACEBO GROUP (n=12)</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) Pulmonary function tests: FVC (L), FEV1 (L), FVC, IC, FRC, Raw, TLC, RV. <BR/>2) Patient diary data.<BR/>3) Dyspnoea, cough, wheezing and sputum production: using a five-point simple scale 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = intolerable. <BR/>4) Side effects: using a simple five-point scale 0 = none; 1= mild; 2 = moderate; 3 = severe; 4 = intolerable.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1) Intention-to-treat analyses: No.<BR/>2) Sample size and statistical power: not reported.<BR/>3) Representativity: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>6MW: Six minute walk distance<BR/>AT: Anaerobic threshold (mlVO2/min)<BR/>DLCO: Diffusing capacity of the lung for carbon monoxide (ml/min/mmHg)<BR/>FEV1: Forced expiratory volume in one second (L)<BR/>FVC: Forced Vital Capacity (L)<BR/>FRC: Functional Residual Capacity (L)<BR/>HR: Heart Rate<BR/>MMFER: Maximal mid flow expiratory rate<BR/>MVV: Maximum Voluntary Ventilation (L)<BR/>PaCO2: Arterial carbon dioxide tension (mmHg or KPa)<BR/>PaO2: Arterial oxygen tension (mmHg or KPa)<BR/>PC20: concentration of inhalent necessary to produce a 20% fall in FEV1<BR/>PEFR: Peak expiratory flow rate <BR/>RV: Residual volume (L)<BR/>SVC: Slow vital capacity (L)<BR/>TGV: Trapped gas volume (L)<BR/>TLC: Total Lung Capacity (L)<BR/>VEmax/MVV: dyspnoea index<BR/>VE/VO2slope: anaerobic threshold <BR/>VO2max/HR : maximum oxygen pulse<BR/>VO2 max: Maximum oxygen consumption <BR/>WR: Work Rate</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adelroth-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arnold-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Study compared enprofylline versus theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ashutosh-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>The objective of this study was to observe the effect theophylline on respiratory drive. The study was also only of single doses of theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bachmann-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients were taking theophylline as study was seeing the effects of cimetidine and famotidine on theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berry-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Because of the objective of this study is investigate the effect to theophylline on sleep-disordered breathing in patients with COPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beulcke-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Study compared two derivatives of xanthine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bleecker-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single dose study lasting 2 hours and probably not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blom-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study did not involve the use of theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boos-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carvalho_x002d_Pinto-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chapman-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>The population studied had reversible obstructive airway disease (asthma)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Conradson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>The population studied have bronchial asthma (23) and/or chronic bronchitis (1).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crimi-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study. Comparison was between nedocromil sodium and theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cusack-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Di-Lorenzo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no control group, only salmeterol and theophylline intervention groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dini-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dorow-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation of treatment not randomised, although double-blinding was used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dull-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study presents data for post isoproterenol nebulisation response on the final day of 4-wk placebo and theophylline period.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evans-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single dose study. Patients were given theophylline at 2200hrs on the eve of each study day and all patients were studies 12 hours later. Varying single doses were used (200, 400, 600 and 800 mg) on separate days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fitzpatrick-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>The subjects included in this study are healthy volunteeers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greening-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>The population is not COPD. They have asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harkaway-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm, study comparing 2 preparations of theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horiguchi-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not COPD but study done in patients with asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hudson-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Javaheri-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The population studied in this paper have heart failure not COPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karpel-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>There are four grops in this study : ipratropium + theophylline + albuterol vs theophylline + albuterol vs ipratropium vs placebo. But there are no theophylline only group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lamont-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study included patients with greater than 20% reversibility in FEV1 after beta2 agonists from pMDI, therefore COPD patients only not included in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lefcoe-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Because of the distribution of the grous: P = placebos (2 oral, plus one aerosol), F + T = fenoterol + teophylline, I = Ipratropium bromide + placebo + theophylline, F+ T + I = fenoterol+ theophylline + ipratropium bromide. So, there is not a isolated theophylline study group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leitch-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single dose study lasting 3 hours.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leuenberger-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT but a review paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lunell-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahon-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was not a conventional RCT but an N of 1 trial, therefore it was excluded as only conventional RCT's were included. Patients in this study switched (crossover) to the "other" blinded treatment arm if the first treatment did not appear to work.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Man-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marlin-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not COPD patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McHardy-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study specifically looked at chronic bronchitis patients only but also included some patients who had COPD. But the data for COPD patients is not presented separately but mentioned in text.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Melani-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no placebo group in this study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Melillo-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morandini-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oren--1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study is not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poukkula-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not patients with COPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pulido-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bamyphylline is a theophylline derivate. Our protocol includes only aminophylline and theophylline not their derivates.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sacco-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>In this study there was no placebo group. It was doxofylline versus theophylline groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shivaram-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single dose study lasting 120 minutes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siemon-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study comparing two different theophylline preparations.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steen-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm in study. Tedral versus theophylline only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutton-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not COPD patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Svedmyr-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single dose study in patients with asthma. Oral theophylline used in combination with terbutaline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taccola-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tanzj-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Two different theophylline preparations compared with no placebo arm in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tatsis-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study does not a placebo group and includes bronchial asthmatics patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taylor-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not COPD patients, mean bronchodilator reversibility in FEV1 of &gt; 26%.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsukino-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single dose study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Umut-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Andel-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vereen-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Use of iv aminophylline preparation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Villani-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Because doxophylline is a theophylline derivate. Our protocol includes only aminophylline and theophylline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vyse-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wiessmann-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation of treatment not randomised, although double-blinding was used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Winter-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Study only included a comparison between theophylline versus salbutamol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not COPD patients but asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ZuWallack-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study was primarily comparing theophylline plus salmeterol as a combination treatment. Although the study had theophylline only arm it did not have a placebo only arm so the study cannot be included in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Alexander-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chrystyn-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dullinger-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fink-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guyatt-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Iversen-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kongragunta-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Machraoui-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mahler-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Marvin-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mulloy-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Murciano-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Newman-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nishimura-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nishimura-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Power-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rivington-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schmidt-1979">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Thomas-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Theophylline versus Placebo - crossover studies</NAME>
<CONT_OUTCOME CHI2="4.86868294333108" CI_END="0.16272212826639967" CI_START="0.04528812255004636" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10400512540822301" ESTIMABLE="YES" I2="0.0" I2_Q="70.41992822811243" ID="CMP-001.01" NO="1" P_CHI2="0.9931810429809479" P_Q="0.06596594522980592" P_Z="5.172237630263862E-4" Q="3.3806544071687608" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="350" TOTAL_2="350" UNITS="" WEIGHT="199.99999999999994" Z="3.4716741333009327">
<NAME>Forced Expiratory Volume in one second</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9448780064161288" CI_END="0.1617001343884611" CI_START="0.04424550771020982" DF="12" EFFECT_SIZE="0.10297282104933546" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.999989681039227" P_Z="5.890376152594271E-4" STUDIES="13" TAU2="0.0" TOTAL_1="244" TOTAL_2="244" WEIGHT="99.99999999999997" Z="3.4366125260616314">
<NAME>FEV1 (litres)</NAME>
<CONT_DATA CI_END="0.22051725281390824" CI_START="-0.06051725281390832" EFFECT_SIZE="0.07999999999999996" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.65" ORDER="7" SD_1="0.17" SD_2="0.15" SE="0.07169379331573969" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="17.467106382195613"/>
<CONT_DATA CI_END="0.4158717078036381" CI_START="-0.1758717078036383" EFFECT_SIZE="0.11999999999999988" ESTIMABLE="YES" MEAN_1="1.46" MEAN_2="1.34" ORDER="8" SD_1="0.43" SD_2="0.45" SE="0.15095772684469533" STUDY_ID="STD-Anderson-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="3.9397928644198577"/>
<CONT_DATA CI_END="0.2815366581976405" CI_START="-0.12153665819764037" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="0.94" ORDER="10" SD_1="0.19" SD_2="0.35" SE="0.10282671507606052" STUDY_ID="STD-Marvin-1983" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.49126041656546"/>
<CONT_DATA CI_END="0.34529886925630243" CI_START="-0.08529886925630265" EFFECT_SIZE="0.1299999999999999" ESTIMABLE="YES" MEAN_1="0.94" MEAN_2="0.81" ORDER="14" SD_1="0.4" SD_2="0.36" SE="0.1098483803552272" STUDY_ID="STD-Guyatt-1987" TOTAL_1="24" TOTAL_2="24" WEIGHT="7.440408298714265"/>
<CONT_DATA CI_END="0.38216930562743173" CI_START="-0.16216930562743198" EFFECT_SIZE="0.10999999999999988" ESTIMABLE="YES" MEAN_1="1.14" MEAN_2="1.03" ORDER="14" SD_1="0.33" SD_2="0.35" SE="0.13886444229295467" STUDY_ID="STD-Thomas-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.655882116049376"/>
<CONT_DATA CI_END="0.37746934460959486" CI_START="-0.1774693446095949" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.9" ORDER="28" SD_1="0.38" SD_2="0.31" SE="0.1415685935038795" STUDY_ID="STD-Nishimura-1993" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.47971360355021"/>
<CONT_DATA CI_END="0.3104786088820919" CI_START="-0.170478608882092" EFFECT_SIZE="0.06999999999999995" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.93" ORDER="28" SD_1="0.43" SD_2="0.42" SE="0.1226954223541639" STUDY_ID="STD-Nishimura-1995" TOTAL_1="24" TOTAL_2="24" WEIGHT="5.963858962932885"/>
<CONT_DATA CI_END="0.37580027058810794" CI_START="-0.07580027058810809" EFFECT_SIZE="0.1499999999999999" ESTIMABLE="YES" MEAN_1="1.15" MEAN_2="1.0" ORDER="28" SD_1="0.53" SD_2="0.5" SE="0.11520633663128084" STUDY_ID="STD-Alexander-1980" TOTAL_1="40" TOTAL_2="40" WEIGHT="6.764432232396719"/>
<CONT_DATA CI_END="0.46611144206237065" CI_START="-0.20611144206237086" EFFECT_SIZE="0.1299999999999999" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.0" ORDER="28" SD_1="0.48" SD_2="0.35" SE="0.1714885807665727" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="3.0529076839156297"/>
<CONT_DATA CI_END="0.25827411514138976" CI_START="0.001725884858610277" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="-0.02" ORDER="28" SD_1="0.17" SD_2="0.15" SE="0.06544717972023954" STUDY_ID="STD-Mahler-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.96052765863474"/>
<CONT_DATA CI_END="0.2628245562224324" CI_START="-0.16282455622243233" EFFECT_SIZE="0.050000000000000044" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.05" ORDER="30" SD_1="0.37" SD_2="0.35" SE="0.10858595254870258" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="7.614419389740479"/>
<CONT_DATA CI_END="0.3336046791482047" CI_START="-0.17360467914820454" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="1.08" MEAN_2="1.0" ORDER="60" SD_1="0.55" SD_2="0.5" SE="0.12939252004047316" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="5.362480696014515"/>
<CONT_DATA CI_END="0.42097937381579914" CI_START="-0.18097937381579915" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="0.9" ORDER="90" SD_1="0.37" SD_2="0.35" SE="0.15356372677757654" STUDY_ID="STD-Schmidt-1979" TOTAL_1="11" TOTAL_2="11" WEIGHT="3.8072096948702394"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5431505297461906" CI_END="6.1768103604675595" CI_START="-0.0904616518089143" DF="2" EFFECT_SIZE="3.043174354329323" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.7621779331379348" P_Z="0.05699047816098942" STUDIES="3" TAU2="0.0" TOTAL_1="106" TOTAL_2="106" WEIGHT="99.99999999999999" Z="1.9033838395646414">
<NAME>FEV1 (% predicted)</NAME>
<CONT_DATA CI_END="12.361899452943648" CI_START="-6.761899452943654" EFFECT_SIZE="2.799999999999997" ESTIMABLE="YES" MEAN_1="38.5" MEAN_2="35.7" ORDER="28" SD_1="16.9" SD_2="16.9" SE="4.878609774652337" STUDY_ID="STD-Nishimura-1995" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.740110562983773"/>
<CONT_DATA CI_END="6.638776912734767" CI_START="-3.238776912734761" EFFECT_SIZE="1.7000000000000028" ESTIMABLE="YES" MEAN_1="39.6" MEAN_2="37.9" ORDER="30" SD_1="8.0" SD_2="8.7" SE="2.5198304416260737" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="40.25856391155624"/>
<CONT_DATA CI_END="8.676562317368955" CI_START="-0.27656231736895" EFFECT_SIZE="4.200000000000003" ESTIMABLE="YES" MEAN_1="35.7" MEAN_2="31.5" ORDER="60" SD_1="13.0" SD_2="12.0" SE="2.284002335083453" STUDY_ID="STD-Murciano-1989" TOTAL_1="60" TOTAL_2="60" WEIGHT="49.001325525459976"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.756215882562503" CI_END="0.3211176911543412" CI_START="0.09901724950783661" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21006747033108888" ESTIMABLE="YES" I2="0.0" I2_Q="74.08346625957637" ID="CMP-001.02" NO="2" P_CHI2="0.9142737644341298" P_Q="0.049493410337878685" P_Z="2.0927090763922743E-4" Q="3.8585406907260826" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="302" TOTAL_2="302" UNITS="" WEIGHT="200.0" Z="3.7075538717538645">
<NAME>Forced Vital Capacity</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.3271304632900103" CI_END="0.3178392382947904" CI_START="0.09563952001266486" DF="10" EFFECT_SIZE="0.20673937915372761" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.9931626248452898" P_Z="2.651290605183411E-4" STUDIES="11" TAU2="0.0" TOTAL_1="196" TOTAL_2="196" WEIGHT="100.0" Z="3.6471849780925023">
<NAME>FVC (litres)</NAME>
<CONT_DATA CI_END="0.4918437908248668" CI_START="-0.19184379082486697" EFFECT_SIZE="0.1499999999999999" ESTIMABLE="YES" MEAN_1="2.78" MEAN_2="2.63" ORDER="7" SD_1="0.39" SD_2="0.39" SE="0.1744133022449836" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.562619244841967"/>
<CONT_DATA CI_END="0.5700526861309753" CI_START="-0.15005268613097533" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="2.64" MEAN_2="2.43" ORDER="8" SD_1="0.51" SD_2="0.56" SE="0.1837037256658923" STUDY_ID="STD-Anderson-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="9.521270553037432"/>
<CONT_DATA CI_END="0.6209410797125456" CI_START="-0.2609410797125453" EFFECT_SIZE="0.18000000000000016" ESTIMABLE="YES" MEAN_1="2.44" MEAN_2="2.26" ORDER="10" SD_1="0.74" SD_2="0.46" SE="0.2249740725802272" STUDY_ID="STD-Marvin-1983" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.34842355297865"/>
<CONT_DATA CI_END="0.6981059853962142" CI_START="-0.23810598539621425" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.1" ORDER="14" SD_1="0.59" SD_2="0.58" SE="0.23883397301612402" STUDY_ID="STD-Thomas-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.632985433363204"/>
<CONT_DATA CI_END="0.6791023320018214" CI_START="-0.07910233200182082" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="2.85" MEAN_2="2.55" ORDER="28" SD_1="0.86" SD_2="0.87" SE="0.193423111338847" STUDY_ID="STD-Alexander-1980" TOTAL_1="40" TOTAL_2="40" WEIGHT="8.588436416387376"/>
<CONT_DATA CI_END="0.7487780960691438" CI_START="-0.4287780960691435" EFFECT_SIZE="0.16000000000000014" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.4" ORDER="28" SD_1="0.77" SD_2="0.7" SE="0.30040250775695376" STUDY_ID="STD-Nishimura-1993" TOTAL_1="12" TOTAL_2="12" WEIGHT="3.560604422510954"/>
<CONT_DATA CI_END="0.7237029331427531" CI_START="-0.12370293314275266" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="2.24" MEAN_2="1.94" ORDER="28" SD_1="0.62" SD_2="0.42" SE="0.21617893822787948" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.875496663939215"/>
<CONT_DATA CI_END="0.43460679016713877" CI_START="-0.0746067901671387" EFFECT_SIZE="0.18000000000000002" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="-0.04" ORDER="28" SD_1="0.27" SD_2="0.36" SE="0.1299038105676658" STUDY_ID="STD-Mahler-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="19.040881625368453"/>
<CONT_DATA CI_END="0.3996129305771677" CI_START="-0.1996129305771675" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.38" MEAN_2="2.28" ORDER="30" SD_1="0.55" SD_2="0.46" SE="0.15286654904910302" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="13.75010173782929"/>
<CONT_DATA CI_END="0.5331251848263581" CI_START="-0.15312518482635812" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" MEAN_1="2.65" MEAN_2="2.46" ORDER="60" SD_1="0.67" SD_2="0.75" SE="0.17506708670816695" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="10.483874782605357"/>
<CONT_DATA CI_END="0.9380096125993527" CI_START="0.0019903874006477196" EFFECT_SIZE="0.4700000000000002" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="1.94" ORDER="90" SD_1="0.56" SD_2="0.56" SE="0.2387848023182837" STUDY_ID="STD-Schmidt-1979" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.635305567138104"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5705447285464101" CI_END="7.647379815034265" CI_START="0.21665521123544673" DF="2" EFFECT_SIZE="3.932017513134856" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.7518094841734315" P_Z="0.038055537718117476" STUDIES="3" TAU2="0.0" TOTAL_1="106" TOTAL_2="106" WEIGHT="100.0" Z="2.0742560445276648">
<NAME>FVC (% predicted)</NAME>
<CONT_DATA CI_END="14.756432387108239" CI_START="-8.156432387108245" EFFECT_SIZE="3.299999999999997" ESTIMABLE="YES" MEAN_1="72.6" MEAN_2="69.3" ORDER="28" SD_1="18.8" SD_2="21.6" SE="5.845225972250061" STUDY_ID="STD-Nishimura-1995" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.517282698866254"/>
<CONT_DATA CI_END="8.162457745581243" CI_START="-3.3624577455812306" EFFECT_SIZE="2.4000000000000057" ESTIMABLE="YES" MEAN_1="67.4" MEAN_2="65.0" ORDER="30" SD_1="9.6" SD_2="9.9" SE="2.9400834867552503" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="41.57065167296525"/>
<CONT_DATA CI_END="10.767582431151478" CI_START="0.03241756884853331" EFFECT_SIZE="5.400000000000006" ESTIMABLE="YES" MEAN_1="63.2" MEAN_2="57.8" ORDER="60" SD_1="15.0" SD_2="15.0" SE="2.7386127875258306" STUDY_ID="STD-Murciano-1989" TOTAL_1="60" TOTAL_2="60" WEIGHT="47.9120656281685"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Slow Vital Capacity (liters)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7960878988781308" CI_START="0.06391210112186946" EFFECT_SIZE="0.43000000000000016" ESTIMABLE="YES" MEAN_1="2.96" MEAN_2="2.53" ORDER="60" SD_1="0.68" SD_2="0.83" SE="0.1867829724248942" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7859448473266029" CI_END="0.3760821871397987" CI_START="-0.6530559192110262" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1384868660356138" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.4094369617770405" P_Q="0.4094369617770406" P_Z="0.5978543866795243" Q="1.7859448473266024" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="126" TOTAL_2="126" UNITS="" WEIGHT="300.0" Z="0.5274885228457341">
<NAME>Functional Residual Capacity</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8429099138165369" CI_START="-0.5429099138165362" DF="0" EFFECT_SIZE="0.15000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.6713544898946083" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.42428978402357004">
<NAME>FRC - measured by helium dilution (liters)</NAME>
<CONT_DATA CI_END="0.8429099138165369" CI_START="-0.5429099138165362" EFFECT_SIZE="0.15000000000000036" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.85" ORDER="60" SD_1="1.49" SD_2="1.38" SE="0.3535319624656991" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9976250086169542E-32" CI_END="0.2897883638071133" CI_START="-1.2497883638071123" DF="0" EFFECT_SIZE="-0.4799999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.0" P_Z="0.22165787411454607" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="1.2221316361895003">
<NAME>FRC - measured by whole body plethysmography (liters)</NAME>
<CONT_DATA CI_END="0.28978836380711326" CI_START="-1.2497883638071123" EFFECT_SIZE="-0.47999999999999954" ESTIMABLE="YES" MEAN_1="6.28" MEAN_2="6.76" ORDER="60" SD_1="1.63" SD_2="1.56" SE="0.39275638219840014" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.544790274097956" CI_START="-16.544790274097956" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="0.532004440372595" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.6249491435777669">
<NAME>FRC (% predicted)</NAME>
<CONT_DATA CI_END="8.544790274097956" CI_START="-16.544790274097956" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="157.0" MEAN_2="161.0" ORDER="60" SD_1="33.0" SD_2="37.0" SE="6.400520812142295" STUDY_ID="STD-Murciano-1989" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.030857491459736167" CI_END="39.037593967053084" CI_START="-9.390887602323078" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="14.823353182365002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.9998821941069985" P_Q="1.0" P_Z="0.23020112749592558" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="98" UNITS="" WEIGHT="100.0" Z="1.1998409789467557">
<NAME>Peak Expiratory Flow Rate (liters/min)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="63.73287536232962" CI_START="-36.73287536232962" EFFECT_SIZE="13.5" ESTIMABLE="YES" MEAN_1="304.1" MEAN_2="290.6" ORDER="8" SD_1="78.34" SD_2="70.92" SE="25.629488989879473" STUDY_ID="STD-Anderson-1982" TOTAL_1="17" TOTAL_2="17" WEIGHT="23.23622841772458"/>
<CONT_DATA CI_END="64.51414981117853" CI_START="-34.51414981117853" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="291.0" MEAN_2="276.0" ORDER="28" SD_1="89.0" SD_2="86.0" SE="25.262785541846597" STUDY_ID="STD-Nishimura-1995" TOTAL_1="24" TOTAL_2="24" WEIGHT="23.91569800268094"/>
<CONT_DATA CI_END="118.02051271799448" CI_START="-98.02051271799448" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="262.0" MEAN_2="252.0" ORDER="28" SD_1="135.0" SD_2="135.0" SE="55.113519212621505" STUDY_ID="STD-Nishimura-1993" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.024921074170974"/>
<CONT_DATA CI_END="120.48644687987554" CI_START="-76.48644687987554" EFFECT_SIZE="22.0" ESTIMABLE="YES" MEAN_1="253.0" MEAN_2="231.0" ORDER="28" SD_1="117.78" SD_2="128.17" SE="50.2491105228076" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.044895176277406"/>
<CONT_DATA CI_END="52.46240860321137" CI_START="-22.462408603211372" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="157.0" MEAN_2="142.0" ORDER="60" SD_1="75.25" SD_2="79.96" SE="19.11382499816837" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="41.77825732914609"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.9727238783972294" CI_END="0.6741803394071393" CI_START="-0.41427230788631886" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1299540157604102" ESTIMABLE="YES" I2="49.308668539437676" I2_Q="49.308668539437676" ID="CMP-001.06" NO="6" P_CHI2="0.16015935271977866" P_Q="0.16015935271977866" P_Z="0.6397750369854031" Q="1.9727238783972294" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="66" UNITS="" WEIGHT="200.0" Z="0.4680133603792567">
<NAME>Total Lung Capacity</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2896976261111694" CI_START="-0.2496976261111703" DF="0" EFFECT_SIZE="0.5199999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.1854592031759975" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="1.3241320193621382">
<NAME>TLC - measured by helium dilution (liters)</NAME>
<CONT_DATA CI_END="1.2896976261111694" CI_START="-0.2496976261111703" EFFECT_SIZE="0.5199999999999996" ESTIMABLE="YES" MEAN_1="7.27" MEAN_2="6.75" ORDER="60" SD_1="1.57" SD_2="1.62" SE="0.3927100866048797" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5096068777171298" CI_START="-1.0296068777171294" DF="0" EFFECT_SIZE="-0.2599999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.5078788940244094" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.6621440773658401">
<NAME>TLC - measured by whole body plethysmography (liters)</NAME>
<CONT_DATA CI_END="0.5096068777171298" CI_START="-1.0296068777171294" EFFECT_SIZE="-0.2599999999999998" ESTIMABLE="YES" MEAN_1="8.32" MEAN_2="8.58" ORDER="60" SD_1="1.6" SD_2="1.59" SE="0.39266378555304604" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Residual Volume (litres)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7185642466257376" CI_START="-1.4985642466257387" EFFECT_SIZE="-0.39000000000000057" ESTIMABLE="YES" MEAN_1="4.34" MEAN_2="4.73" ORDER="14" SD_1="1.42" SD_2="1.35" SE="0.5656043964939924" STUDY_ID="STD-Thomas-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Trapped gas volume (liters)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.39246347623583655" CI_START="-1.1875365237641635" EFFECT_SIZE="-0.79" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.84" ORDER="60" SD_1="0.74" SD_2="0.9" SE="0.2028284840435237" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7369963927434536" CI_END="277.82511324643355" CI_START="112.70958689470426" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="195.2673500705689" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.3906247715478478" P_Q="1.0" P_Z="3.556492852912858E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" UNITS="" WEIGHT="100.00000000000001" Z="4.635747854258427">
<NAME>VO2max -maximum oxygen consumption (ml/min)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="309.0496841064886" CI_START="120.9503158935114" EFFECT_SIZE="215.0" ESTIMABLE="YES" MEAN_1="1713.0" MEAN_2="1498.0" ORDER="28" SD_1="115.0" SD_2="99.0" SE="47.985414450643226" STUDY_ID="STD-Newman-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="77.05505822159174"/>
<CONT_DATA CI_END="301.3512500385193" CI_START="-43.35125003851934" EFFECT_SIZE="129.0" ESTIMABLE="YES" MEAN_1="1195.0" MEAN_2="1066.0" ORDER="30" SD_1="334.0" SD_2="242.0" SE="87.93592708743834" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="22.944941778408282"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.97030477618239" CI_END="5.127624040668314" CI_START="1.2306813119024904" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="3.179152676285402" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.4195151478880186" P_Q="1.0" P_Z="0.0013843026291575048" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="156" UNITS="" WEIGHT="99.99999999999999" Z="3.1979041933967056">
<NAME>PaO2 mmHg (arterial oxygen tension at rest)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.021695061171425" CI_START="-0.8216950611714076" EFFECT_SIZE="9.100000000000009" ESTIMABLE="YES" MEAN_1="78.9" MEAN_2="69.8" ORDER="21" SD_1="11.63" SD_2="11.0" SE="5.062182335712533" STUDY_ID="STD-Mulloy-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.85670397142509"/>
<CONT_DATA CI_END="7.268624593589811" CI_START="-0.6686245935898163" EFFECT_SIZE="3.299999999999997" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="66.7" ORDER="28" SD_1="8.0" SD_2="10.0" SE="2.0248456731316584" STUDY_ID="STD-Alexander-1980" TOTAL_1="40" TOTAL_2="40" WEIGHT="24.10504887646542"/>
<CONT_DATA CI_END="4.545052986190384" CI_START="-6.545052986190384" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="68.0" ORDER="28" SD_1="6.93" SD_2="6.93" SE="2.8291606529145708" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="12.347432318673217"/>
<CONT_DATA CI_END="10.862416506304644" CI_START="-5.062416506304643" EFFECT_SIZE="2.9" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="0.6" ORDER="28" SD_1="9.8" SD_2="10.1" SE="4.0625320511556176" STUDY_ID="STD-Mahler-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.988227239192621"/>
<CONT_DATA CI_END="5.881310557888593" CI_START="-1.0813105578886097" EFFECT_SIZE="2.3999999999999915" ESTIMABLE="YES" MEAN_1="66.83" MEAN_2="64.43" ORDER="30" SD_1="5.78" SD_2="6.0" SE="1.7762114943686387" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="31.32582524099649"/>
<CONT_DATA CI_END="9.619034246608347" CI_START="1.3809657533916537" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="60.5" ORDER="60" SD_1="11.0" SD_2="12.0" SE="2.1015867021530816" STUDY_ID="STD-Murciano-1989" TOTAL_1="60" TOTAL_2="60" WEIGHT="22.37676235324715"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.728142958198984" CI_END="-1.2060693068058281" CI_START="-3.517877156370882" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.361973231588355" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.5891817507269235" P_Q="1.0" P_Z="6.20203756420125E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="156" UNITS="" WEIGHT="99.99999999999999" Z="4.0049889676011245">
<NAME>PaCO2 mmHg (arterial carbon dioxide tension at rest)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.838386891062159" CI_START="-6.4383868910621675" EFFECT_SIZE="-2.8000000000000043" ESTIMABLE="YES" MEAN_1="42.8" MEAN_2="45.6" ORDER="21" SD_1="4.66" SD_2="3.57" SE="1.8563539533181705" STUDY_ID="STD-Mulloy-1993" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.093126586896846"/>
<CONT_DATA CI_END="2.382484874814887" CI_START="-6.382484874814887" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="39.0" ORDER="28" SD_1="3.46" SD_2="6.93" SE="2.2360027578993127" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.956689581847451"/>
<CONT_DATA CI_END="0.13150423219534568" CI_START="-4.931504232195357" EFFECT_SIZE="-2.4000000000000057" ESTIMABLE="YES" MEAN_1="36.3" MEAN_2="38.7" ORDER="28" SD_1="5.2" SD_2="6.3" SE="1.291607525527782" STUDY_ID="STD-Alexander-1980" TOTAL_1="40" TOTAL_2="40" WEIGHT="20.849044732369777"/>
<CONT_DATA CI_END="1.865800380132431" CI_START="-6.065800380132432" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="1.2" ORDER="28" SD_1="5.2" SD_2="4.7" SE="2.0234047214204742" STUDY_ID="STD-Mahler-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.495359790297385"/>
<CONT_DATA CI_END="0.5362553272892019" CI_START="-3.2362553272892045" EFFECT_SIZE="-1.3500000000000014" ESTIMABLE="YES" MEAN_1="40.35" MEAN_2="41.7" ORDER="30" SD_1="3.08" SD_2="3.3" SE="0.9623928511787688" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="37.55281675099966"/>
<CONT_DATA CI_END="-1.8150111303211944" CI_START="-7.584988869678812" EFFECT_SIZE="-4.700000000000003" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="48.7" ORDER="60" SD_1="7.0" SD_2="9.0" SE="1.4719601443879746" STUDY_ID="STD-Murciano-1989" TOTAL_1="60" TOTAL_2="60" WEIGHT="16.052962557588867"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>SaO2 (oxygen saturation at rest %)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0833792088369645" CI_START="-0.2833792088369529" EFFECT_SIZE="0.9000000000000057" ESTIMABLE="YES" MEAN_1="96.7" MEAN_2="95.8" ORDER="7" SD_1="1.9" SD_2="2.1" SE="0.6037759969934666" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5112806433775441" CI_END="0.6157883440819689" CI_START="-0.010644908821481114" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3025717176302439" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="0.91640626589356" P_Q="0.6168253963652496" P_Z="0.05831092859180847" Q="0.2503548003334269" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="80" UNITS="" WEIGHT="100.0" Z="1.8933530956317308">
<NAME>Distance walked (m)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.2609108879552968" CI_END="0.6209360341177337" CI_START="-0.11382068122599392" DF="1" EFFECT_SIZE="0.25355767644586985" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="0.6094950946287155" P_Z="0.17614173910329384" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="58" WEIGHT="72.68795967249622" Z="1.3527305119085018">
<NAME>6MWD</NAME>
<CONT_DATA CI_END="0.9306505711982197" CI_START="-0.19968224190154682" EFFECT_SIZE="0.36548416464833644" ESTIMABLE="YES" MEAN_1="430.0" MEAN_2="392.0" ORDER="14" SD_1="96.0" SD_2="108.0" SE="0.2883555060235003" STUDY_ID="STD-Guyatt-1987" TOTAL_1="24" TOTAL_2="25" WEIGHT="30.714039340596702"/>
<CONT_DATA CI_END="0.6551103432009275" CI_START="-0.3117973959326046" EFFECT_SIZE="0.17165647363416148" ESTIMABLE="YES" MEAN_1="316.0" MEAN_2="290.0" ORDER="60" SD_1="152.81" SD_2="146.49" SE="0.24666467005526044" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" WEIGHT="41.973920331899514"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4955088820415575E-5" CI_END="1.032349511132791" CI_START="-0.16631523020317857" DF="1" EFFECT_SIZE="0.43301714046480616" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="0.9969144436839568" P_Z="0.15675432190869046" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="27.312040327503777" Z="1.4160723523970968">
<NAME>12MWD</NAME>
<CONT_DATA CI_END="1.3236115843084406" CI_START="-0.45498465745215727" EFFECT_SIZE="0.43431346342814164" ESTIMABLE="YES" MEAN_1="798.0" MEAN_2="764.0" ORDER="7" SD_1="71.51" SD_2="78.29" SE="0.45373186849093605" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.404945653623384"/>
<CONT_DATA CI_END="1.243176436677162" CI_START="-0.3792996272416963" EFFECT_SIZE="0.4319384047177328" ESTIMABLE="YES" MEAN_1="18.4" MEAN_2="-5.5" ORDER="28" SD_1="55.0" SD_2="51.8" SE="0.4139045606747732" STUDY_ID="STD-Mahler-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.907094673880392"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.005839388602362742" CI_END="11.840483201241904" CI_START="-4.62000651299123" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.6102383441253365" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" NO="14" P_CHI2="0.9390882264294741" P_Q="1.0" P_Z="0.3899279394860289" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="32" UNITS="" WEIGHT="100.0" Z="0.8597480698247668">
<NAME>VAS (mm) 0 = extremely breathlessness, 100 = not at all breathless</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.239417434025988" CI_START="-6.439417434025977" EFFECT_SIZE="3.4000000000000057" ESTIMABLE="YES" MEAN_1="56.7" MEAN_2="53.3" ORDER="7" SD_1="10.62" SD_2="11.8" SE="5.020203183139104" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="69.96595083923823"/>
<CONT_DATA CI_END="19.117782575353722" CI_START="-10.917782575353721" EFFECT_SIZE="4.100000000000001" ESTIMABLE="YES" MEAN_1="54.6" MEAN_2="50.5" ORDER="930" SD_1="22.2" SD_2="19.7" SE="7.662274763114055" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="12" TOTAL_2="22" WEIGHT="30.034049160761768"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Duration of resistive breathing (60% of Pimax - minutes)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.121754823014842" CI_START="-1.221754823014843" EFFECT_SIZE="0.44999999999999973" ESTIMABLE="YES" MEAN_1="3.51" MEAN_2="3.06" ORDER="3" SD_1="1.51" SD_2="1.76" SE="0.8529518073808658" STUDY_ID="STD-Kongragunta-1988" TOTAL_1="8" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2691076466823836" CI_END="0.8490853048229531" CI_START="-0.7572438291318934" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04592073784552988" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="0.603931049582403" P_Q="0.603931049582403" P_Z="0.9107754667921745" Q="0.2691076466823836" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="200.0" Z="0.11206046185460516">
<NAME>Exercise challenge</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.833809196596318" CI_START="-2.773809196596319" DF="0" EFFECT_SIZE="1.0299999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" NO="1" P_CHI2="1.0" P_Z="0.5956118634058039" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0" Z="0.5307213899905024">
<NAME>Cycle endurane testing (minutes)</NAME>
<CONT_DATA CI_END="4.833809196596318" CI_START="-2.773809196596319" EFFECT_SIZE="1.0299999999999994" ESTIMABLE="YES" MEAN_1="5.43" MEAN_2="4.4" ORDER="3" SD_1="4.16" SD_2="3.01" SE="1.9407546396771982" STUDY_ID="STD-Kongragunta-1988" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.821690210678696" CI_START="-0.821690210678696" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>Progressive Cycle Ergometry (PCE) (min)</NAME>
<CONT_DATA CI_END="0.821690210678696" CI_START="-0.821690210678696" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.3" ORDER="7" SD_1="0.74" SD_2="1.1" SE="0.4192374029115246" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Heart rate (bpm)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Lower with Theo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower with Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.256182880497093" CI_START="0.14381711950288523" EFFECT_SIZE="6.699999999999989" ESTIMABLE="YES" MEAN_1="90.6" MEAN_2="83.9" ORDER="4" SD_1="13.6" SD_2="12.3" SE="3.345052731688662" STUDY_ID="STD-Machraoui-1994" TOTAL_1="36" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1584080327734871" CI_END="0.08608762677501774" CI_START="-0.5559351232848477" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.23492374825491497" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="0.9840066502151831" P_Q="0.7112508068332863" P_Z="0.1514729238964184" Q="0.13703092187623117" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="200.0" Z="1.4343481929568813">
<NAME>Symptoms</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.014012798355831656" CI_END="0.19465015472840932" CI_START="-0.5819676380298247" DF="1" EFFECT_SIZE="-0.19365874165070765" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" NO="1" P_CHI2="0.905770008193547" P_Z="0.3283316139135207" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.9774799456465574">
<NAME>Wheezing (simple scales)</NAME>
<CONT_DATA CI_END="0.5192342779670094" CI_START="-0.8392342779670094" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.51" ORDER="10" SD_1="0.75" SD_2="0.72" SE="0.34655446902326914" STUDY_ID="STD-Marvin-1983" TOTAL_1="9" TOTAL_2="9" WEIGHT="32.682516698584706"/>
<CONT_DATA CI_END="0.26327482650496703" CI_START="-0.6832748265049671" EFFECT_SIZE="-0.21000000000000002" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="0.52" ORDER="14" SD_1="0.39" SD_2="0.74" SE="0.24147118530651504" STUDY_ID="STD-Thomas-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="67.3174833014153"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.007364312541424304" CI_END="0.24652412698021353" CI_START="-0.8945320804377582" DF="1" EFFECT_SIZE="-0.32400397672877235" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.02" NO="2" P_CHI2="0.931613027072733" P_Z="0.2656795825212944" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="99.99999999999999" Z="1.1130672110765396">
<NAME>Shortness of breath (simple scales)</NAME>
<CONT_DATA CI_END="0.47341816949379556" CI_START="-1.1734181694937957" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.05" ORDER="10" SD_1="0.78" SD_2="0.99" SE="0.4201190307520001" STUDY_ID="STD-Marvin-1983" TOTAL_1="9" TOTAL_2="9" WEIGHT="48.00795345754474"/>
<CONT_DATA CI_END="0.4912406405782159" CI_START="-1.0912406405782158" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="0.84" MEAN_2="1.14" ORDER="14" SD_1="0.81" SD_2="1.14" SE="0.40370162248868907" STUDY_ID="STD-Thomas-1992" TOTAL_1="12" TOTAL_2="12" WEIGHT="51.99204654245525"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.19" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PC20 (mg/ml)</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1716000640195995" CI_START="-0.0916000640195995" EFFECT_SIZE="0.04000000000000001" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.19" ORDER="28" SD_1="0.21" SD_2="0.1" SE="0.06714412359494562" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.0133027075747845" CI_END="1.1430182287947896" CI_START="0.09720852066223631" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="50.3303702797581" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.05805315655614025" LOG_CI_START="-1.0122956659954654" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="20" P_CHI2="0.15592593195129234" P_Q="1.0" P_Z="0.08057552156273604" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="1.747356480067531">
<NAME>Acute exacerbations</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0032603571059673" CI_START="0.020341841597505232" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.0014136518454501183" LOG_CI_START="-1.6916097318739638" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="14" O_E="0.0" SE="0.9944903161976938" STUDY_ID="STD-Rivington-1988" TOTAL_1="13" TOTAL_2="13" VAR="0.989010989010989" WEIGHT="77.77777777777777"/>
<DICH_DATA CI_END="6.670714447920194" CI_START="0.14990898018604015" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8241723502842975" LOG_CI_START="-0.8241723502842975" LOG_EFFECT_SIZE="0.0" ORDER="28" O_E="0.0" SE="0.9682458365518543" STUDY_ID="STD-Nishimura-1995" TOTAL_1="32" TOTAL_2="32" VAR="0.9375" WEIGHT="22.22222222222222"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0372906601263312" CI_END="4.111147272028968" CI_START="1.256410659705978" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" I2="3.5950058705618333" I2_Q="100.0" ID="CMP-001.21" LOG_CI_END="0.6139630346212422" LOG_CI_START="0.09913161240638298" LOG_EFFECT_SIZE="0.35654732351381263" METHOD="MH" NO="21" P_CHI2="0.3084527591887064" P_Q="0.0" P_Z="0.00663253429631655" Q="1.3477680724141288E-31" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.00000000000001" Z="2.714752374145411">
<NAME>Patient preference for theophylline or placebo</NAME>
<GROUP_LABEL_1>Prefer theophylline</GROUP_LABEL_1>
<GROUP_LABEL_2>Prefer placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Theophylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7238395844736614" CI_START="0.9581243105755852" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.5709909641786798" LOG_CI_START="-0.018578140300781705" LOG_EFFECT_SIZE="0.27620641193894907" ORDER="8" O_E="0.0" SE="0.3463158103853704" STUDY_ID="STD-Alexander-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.11993464052287583" WEIGHT="81.81818181818183"/>
<DICH_DATA CI_END="14.354084750922915" CI_START="1.114665287103816" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.1569755061118119" LOG_CI_START="0.04714447654411281" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="21" O_E="0.0" SE="0.6519202405202649" STUDY_ID="STD-Mulloy-1993" TOTAL_1="10" TOTAL_2="10" VAR="0.42500000000000004" WEIGHT="18.181818181818183"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7633577414555113" CI_START="0.23160229687195705" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.4414371118737813" LOG_CI_START="-0.6352571378898941" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.7242226896387851" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="74" WEIGHT="100.0" Z="0.3528209336657809">
<NAME>Drop-outs</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7633577414555113" CI_START="0.23160229687195705" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4414371118737813" LOG_CI_START="-0.6352571378898941" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="8" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Anderson-1982" TOTAL_1="40" TOTAL_2="40" VAR="0.39999999999999997" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28" O_E="0.0" SE="0.0" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30" O_E="0.0" SE="0.0" STUDY_ID="STD-Fink-1994" TOTAL_1="22" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2941631639005364" CI_END="10.102183280500642" CI_START="1.3308454292642935" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="0.0" I2_Q="1.9163261038363275" ID="CMP-001.23" LOG_CI_END="1.0044152435059692" LOG_CI_START="0.12412761737115605" LOG_EFFECT_SIZE="0.5642714304385625" METHOD="MH" NO="23" P_CHI2="0.6547354825763385" P_Q="0.38267643221831005" P_Z="0.011980937989771368" Q="3.058612999321326" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="101" WEIGHT="400.0" Z="2.5127052757074844">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Theophylline Group</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo Group</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Theophylline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.494679848349412" CI_END="39.941620375216786" CI_START="1.47159221948463" DF="2" EFFECT_SIZE="7.666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="1.6014256796068072" LOG_CI_START="0.1677874829890539" LOG_EFFECT_SIZE="0.8846065812979305" NO="1" P_CHI2="0.780875219103667" P_Z="0.015574486376384478" STUDIES="3" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0" Z="2.418737229408969">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="214.05089475700316" CI_START="0.789531854991093" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.330517047574285" LOG_CI_START="-0.10263034296061159" LOG_EFFECT_SIZE="1.1139433523068367" ORDER="8" O_E="0.0" SE="1.429242821474029" STUDY_ID="STD-Anderson-1982" TOTAL_1="17" TOTAL_2="17" VAR="2.042735042735043" WEIGHT="33.333333333333336"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="21" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Mulloy-1993" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="33.333333333333336"/>
<DICH_DATA CI_END="122.44201077090914" CI_START="0.40018944226324205" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.087930453067895" LOG_CI_START="-0.39773437303938114" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="28" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="33.333333333333336"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.649243330266568" CI_START="0.01452576500886906" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="0.8836184764944177" LOG_CI_START="-1.8378609859337425" LOG_EFFECT_SIZE="-0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.4919381264121142" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="0.6872294929425984">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="7.649243330266568" CI_START="0.01452576500886906" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8836184764944177" LOG_CI_START="-1.8378609859337425" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="8" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Anderson-1982" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.378276515414786" CI_START="0.3287277778399503" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.23.03" LOG_CI_END="1.4374061054705847" LOG_CI_START="-0.4831635960312598" LOG_EFFECT_SIZE="0.47712125471966244" NO="3" P_CHI2="1.0" P_Z="0.3301480628506114" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.9738157118461672">
<NAME>Dyspepsia</NAME>
<DICH_DATA CI_END="27.378276515414786" CI_START="0.3287277778399503" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4374061054705847" LOG_CI_START="-0.4831635960312598" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="60" O_E="0.0" SE="1.1281521496355325" STUDY_ID="STD-Chrystyn-1988" TOTAL_1="33" TOTAL_2="33" VAR="1.2727272727272727" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.05568402675195" CI_START="0.13421680996363317" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.23.04" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" NO="4" P_CHI2="1.0" P_Z="0.4882790296766242" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Headaches</NAME>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="28" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Newman-1994" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>inconsistent (?) reporting</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>Dear Madam or Sir,</P>
<P>
<BR/>I have encountered the difficulty interpreting the results of the review <BR/>by Ram et al. "Oral theophylline for chronic obstructive pulmonary disease".</P>
<P>
<BR/>1. In Results section it states: "Two studies with a total of 100 <BR/>subjects (Anderson 1982, Mulloy 1993) reported that subjects preferred <BR/>theophylline..."</P>
<P>2. In the metaview graph we see 50 patients (cross-over): 40 in Anderson <BR/>study and 10 in Mulloy study.</P>
<P>3. In "Cachacteristics of the included studies" section, we read:</P>
<P>- Anderson 1982: Number of patients: 21 (I have confirmed that with <BR/>Medline abstract)</P>
<P>- Mulloy: Number of patients: 10</P>
<P>
<BR/>My problem is the final number of patients that expressed their <BR/>preference towards theophylline. Is it 100, as the authors say, 50 as <BR/>appears from the metaview graph, or 31 (10 - Mulloy and 21 - Anderson) <BR/>as one would expect from the total number of subjects in both trials?</P>
<P>
<BR/>I would appreciate your prompt response.</P>
<P>
<BR/>Sincerely,</P>
<P>
<BR/>Jan Brozek</P>
<P>
<BR/>I certify that I have no affiliations with or involvement in any <BR/>organisation or entity with a direct financial interest in the subject <BR/>matter of my criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Dear Dr Brozek,</P>
<P>
<BR/>Thank you for your interest in our review. You are correct in pointing <BR/>out that the patient numbers do not add-up from the two studies for the <BR/>outcome "preference".</P>
<P>The numbers in the results and meta-view are correct as they stand but <BR/>unfortunately an incorrect reference was entered for one of the studies. <BR/>Anderson 1982 should read as Alexander 1980.</P>
<P>In addition, the total number of patients in the results section should <BR/>read as 50 (cross-over) not 100.</P>
<P>
<BR/>Once again thank you for your interest in our review and we apologise <BR/>for the incorrect study reference. We will correct this error for the <BR/>next issue of the Cochrane library.</P>
<P>
<BR/>Sincerely</P>
<P>
<BR/>Felix Ram</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Brozek J.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>